alanine has been researched along with Pneumonia, Viral in 251 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previously postulated that the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2." | 3.96 | Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. ( Chien, M; Jockusch, S; Ju, J; Kalachikov, S; Kumar, S; Li, X; Morozova, I; Russo, JJ; Tao, C, 2020) |
| " All adverse events were grade 1 or 2 in severity." | 2.94 | Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. ( Cao, H; Chng, E; German, P; Humeniuk, R; Ling, J; Mathias, A; Osinusi, A; Shen, G; Vu, A, 2020) |
| " Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d." | 2.94 | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. ( Ahn, MY; Arribas López, JR; Bernasconi, E; Bhagani, S; Blair, C; Brainard, DM; Cao, H; Castagna, A; Cattelan, AM; Chai, LYA; Chang, SC; Criner, GJ; Gaggar, A; Gottlieb, RL; Huhn, G; Hyland, RH; Le Turnier, P; Malhotra, P; Marty, FM; McPhail, MJ; Mullane, KM; Ogbuagu, O; Osinusi, AO; Roestenberg, M; Sanyal, AJ; SenGupta, D; Soriano Viladomiu, A; Spinner, CD; Tsang, OTY; Wang, H, 2020) |
| "To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials." | 2.94 | Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. ( Ader, F, 2020) |
| "Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide." | 2.66 | Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. ( Hsueh, PR; Hsueh, SC; Ko, WC; Lai, CC; Liu, YH; Wang, CY; Wang, YH; Yen, MY, 2020) |
| "The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world." | 2.66 | Potential therapeutic agents against COVID-19: What we know so far. ( Chang, YL; Chen, MY; Lee, WS; Lu, CC, 2020) |
| "Your community is in the midst of the coronavirus disease 2019 (COVID-19) pandemic." | 2.66 | Just the facts: What drugs are safe and effective for COVID-19? ( Gottlieb, M; Hicks, C; Liang, SY; Long, B; Rosenberg, H, 2020) |
| "Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended." | 2.66 | Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. ( Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM, 2020) |
| "The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals." | 2.66 | Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. ( Dresser, LD; Jorgensen, SCJ; Kebriaei, R, 2020) |
| "Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician." | 2.66 | Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. ( Bergan, S; Elens, L; Hesselink, DA; Langman, LJ; Lemaitre, F; Moes, DJAR; Molinaro, M; Venkataramanan, R, 2020) |
| "The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown." | 2.66 | Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. ( Ardura, M; Auletta, JJ; Dandoy, C; Hartley, D; Jaglowski, S; Lehmann, L, 2020) |
| "Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system." | 2.66 | A current review of COVID-19 for the cardiovascular specialist. ( Bohula, EA; Lang, JP; Morrow, DA; Moura, FA; Siddiqi, HK; Wang, X, 2020) |
| "Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic." | 2.66 | Medical treatment options for COVID-19. ( Delang, L; Neyts, J, 2020) |
| "The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic." | 2.66 | Clinical management of COVID-19. ( Abraham, OC; John, R; Karthik, R; Manesh, A; Varghese, GM, 2020) |
| "Now, it has been evidenced that Covid19 (SARS-CoV-2) infects the brain tissues." | 2.66 | CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection. ( Danta, CC, 2020) |
| "The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019." | 2.66 | Is hydroxychloroquine beneficial for COVID-19 patients? ( Agostinis, P; Carafoli, E; Li, X; Melino, G; Rabson, A; Shi, Y; Sun, E; Wang, Y, 2020) |
| "With the emergence of coronavirus disease 2019 (COVID-19) in late December 2019, many clinical studies on a group of the pre-existing medications have been conducted to treat this disease." | 2.66 | Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. ( Dizaye, K; Marouf, BH, 2020) |
| "Umifenovir (Arbidol) was associated with reduction in mortality in few studies." | 2.66 | Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. ( Al-Yamani, MJ; Asdaq, SMB; Jomah, S, 2020) |
| "Lopinavir-ritonavir was significantly associated with shorter mean time to clinical recovery (SMD -0." | 2.66 | Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. ( Hadda, V; Misra, S; Nath, M; Vibha, D, 2020) |
| "The emergence of coronavirus disease 2019 (COVID-19) in December 2019 has resulted in over 20 million cases and 741,808 deaths globally, affecting more than 200 countries." | 2.66 | Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. ( Adewale, OB; Akanbi, MO; Bakare, OO; Fadaka, AO; Klein, A; Madiehe, AM; Meyer, M; Sibuyi, NRS, 2020) |
| " We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19." | 2.66 | Remdesivir-COVID-19: drug interactions in dentistry. ( Gómez-Moreno, G, 2020) |
| "Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses." | 1.56 | Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. ( Antonucci, M; Avataneo, V; Cusato, J; D'Avolio, A; de Nicolò, A; di Perri, G; Lamorde, M; Manca, A; Palermiti, A; Waitt, C; Walimbwa, S, 2020) |
| "Severe sepsis and septic shock syndromes were observed in 7 (53." | 1.56 | Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. ( Aldrich, M; Cabana, MD; Chao, JY; Derespina, KR; Goldman, DL; Herold, BC; Medar, SS; Ushay, HM; Weingarten, J, 2020) |
| "One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure." | 1.56 | Early experience with remdesivir in SARS-CoV-2 pneumonia. ( Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R, 2020) |
| "Among 2,186 U." | 1.56 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. ( Arcobello, J; Bakouny, Z; Choueiri, TK; de Lima Lopes, G; Doroshow, DB; Egan, PC; Farmakiotis, D; Fecher, LA; Friese, CR; Galsky, MD; Goel, S; Grivas, P; Gupta, S; Halfdanarson, TR; Halmos, B; Hawley, JE; Hsu, CY; Khaki, AR; Kuderer, NM; Lee, BJ; Lemmon, CA; Lyman, GH; Mishra, S; Olszewski, AJ; Painter, CA; Panagiotou, OA; Pennell, NA; Peters, S; Puc, MM; Revankar, SG; Rini, BI; Rivera, DR; Rubinstein, SM; Schapira, L; Schmidt, A; Schwartz, GK; Shah, DP; Shah, SA; Shyr, Y; Thompson, MA; Warner, JL; Wu, JT; Xie, Z; Yeh, AC; Zhu, H, 2020) |
| " The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19." | 1.56 | 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. ( Ahmad, SI, 2020) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments." | 1.56 | Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. ( Cihlar, T; Cronin, J; de Wit, E; Feldmann, F; Feldmann, H; Jordan, R; Okumura, A; Scott, D; Thomas, T, 2020) |
| "Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed." | 1.56 | Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. ( Anzick, S; Barbian, K; Bosio, CM; Cihlar, T; de Wit, E; Feldmann, F; Hanley, PW; Leighton, I; Lovaglio, J; Martens, C; Meade-White, K; Munster, VJ; Okumura, A; Pérez-Pérez, L; Porter, DP; Saturday, G; Schulz, J; Schwarz, B; Scott, DP; van Doremalen, N; Williamson, BN; Yinda, CK, 2020) |
| "Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error)." | 1.56 | Compassionate Use of Remdesivir for Patients with Severe Covid-19. ( Ahmed, S; Asperges, E; Bernett, J; Brainard, DM; Cao, H; Castagna, A; Chelliah, D; Chen, D; Chihara, S; Childs, R; Chokkalingam, A; Cohen, SH; Cunningham, J; D'Arminio Monforte, A; Desai, P; DeZure, A; Diaz, G; Elboudwarej, E; Feldt, T; Flanigan, T; Gaggar, A; Green, G; Green, ML; Grein, J; Henne, I; Ismail, S; Kato, H; L'Her, E; Lapadula, G; Lescure, FX; Maeno, T; Majumder, S; Massari, M; Mera, R; Mora-Rillo, M; Mutoh, Y; Myers, RP; Nguyen, D; Nicastri, E; Oda, R; Ohmagari, N; Osinusi, AO; Quiros-Roldan, E; Redinski, J; Sellers, S; Shin, D; Studemeister, A; Tan, SK; Telep, L; Timbs, L; Verweij, E; Winterbourne, L; Yo, K; Zhao, Y; Zhong, L; Zoufaly, A, 2020) |
| "We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients." | 1.56 | Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ( Agrati, C; Ascoli Bartoli, T; Avataneo, V; Capobianchi, MR; Caputi, P; Castilletti, C; D'Avolio, A; Forini, O; Ippolito, G; Lalle, E; Marchioni, L; Nicastri, E; Notari, S; Scorzolini, L; Tempestilli, M, 2020) |
| "Hydroxychloroquine (HCQ) was used by 78." | 1.56 | Early impact of COVID-19 on transplant center practices and policies in the United States. ( Avery, RK; Boyarsky, BJ; Durand, CM; Garonzik-Wang, JM; Getsin, SN; Jackson, KR; Kernodle, AB; Massie, AB; Po-Yu Chiang, T; Segev, DL; Van Pilsum Rasmussen, SE; Werbel, WA, 2020) |
| " Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine." | 1.56 | Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ( Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 251 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, NMD | 1 |
| Heath, PT | 1 |
| Doerholt, K | 1 |
| Almario-Hernandez, AF | 1 |
| Gilmour, C | 1 |
| Drysdale, SB | 1 |
| Ferrara, F | 1 |
| Zovi, A | 1 |
| Trama, U | 1 |
| Vitiello, A | 1 |
| Heyer, A | 1 |
| Günther, T | 1 |
| Robitaille, A | 1 |
| Lütgehetmann, M | 1 |
| Addo, MM | 1 |
| Jarczak, D | 1 |
| Kluge, S | 1 |
| Aepfelbacher, M | 1 |
| Schulze Zur Wiesch, J | 1 |
| Fischer, N | 1 |
| Grundhoff, A | 1 |
| Lu, H | 1 |
| Wang, M | 1 |
| Cao, R | 1 |
| Zhang, L | 1 |
| Yang, X | 1 |
| Liu, J | 1 |
| Xu, M | 1 |
| Shi, Z | 2 |
| Hu, Z | 1 |
| Zhong, W | 1 |
| Xiao, G | 1 |
| de Wit, E | 2 |
| Feldmann, F | 2 |
| Cronin, J | 1 |
| Jordan, R | 1 |
| Okumura, A | 2 |
| Thomas, T | 1 |
| Scott, D | 1 |
| Cihlar, T | 2 |
| Feldmann, H | 1 |
| Maxmen, A | 1 |
| Sun, P | 1 |
| Lu, X | 2 |
| Xu, C | 1 |
| Sun, W | 1 |
| Pan, B | 1 |
| Zhang, Q | 1 |
| Wang, Y | 8 |
| Qi, C | 1 |
| Shen, L | 1 |
| Li, J | 1 |
| Elfiky, AA | 1 |
| Li, G | 2 |
| De Clercq, E | 1 |
| Anderson, PO | 1 |
| Colson, P | 1 |
| Rolain, JM | 2 |
| Lagier, JC | 1 |
| Brouqui, P | 1 |
| Raoult, D | 1 |
| Ko, WC | 2 |
| Lee, NY | 1 |
| Chen, PL | 1 |
| Huang, CT | 1 |
| Lee, PI | 2 |
| Hsueh, PR | 3 |
| Dong, L | 2 |
| Hu, S | 1 |
| Gao, J | 1 |
| Martinez, MA | 2 |
| Du, B | 1 |
| Qiu, HB | 1 |
| Zhan, X | 1 |
| Wang, YS | 1 |
| Kang, HYJ | 1 |
| Li, XY | 1 |
| Wang, F | 1 |
| Sun, B | 1 |
| Tong, ZH | 1 |
| Lai, CC | 1 |
| Liu, YH | 1 |
| Wang, CY | 1 |
| Wang, YH | 1 |
| Hsueh, SC | 1 |
| Yen, MY | 1 |
| Duan, Y | 1 |
| Zhu, HL | 1 |
| Zhou, C | 1 |
| Carradori, S | 1 |
| Atluri, S | 1 |
| Manchikanti, L | 1 |
| Hirsch, JA | 1 |
| Kupferschmidt, K | 1 |
| Cohen, J | 1 |
| Reina, J | 1 |
| Spinelli, FR | 1 |
| Ceccarelli, F | 1 |
| Di Franco, M | 1 |
| Conti, F | 1 |
| Lu, CC | 1 |
| Chen, MY | 1 |
| Lee, WS | 1 |
| Chang, YL | 1 |
| Choy, KT | 1 |
| Wong, AY | 1 |
| Kaewpreedee, P | 1 |
| Sia, SF | 1 |
| Chen, D | 3 |
| Hui, KPY | 1 |
| Chu, DKW | 1 |
| Chan, MCW | 1 |
| Cheung, PP | 1 |
| Huang, X | 1 |
| Peiris, M | 1 |
| Yen, HL | 1 |
| Sheahan, TP | 1 |
| Sims, AC | 1 |
| Zhou, S | 1 |
| Graham, RL | 1 |
| Pruijssers, AJ | 1 |
| Agostini, ML | 1 |
| Leist, SR | 1 |
| Schäfer, A | 1 |
| Dinnon, KH | 1 |
| Stevens, LJ | 1 |
| Chappell, JD | 1 |
| Hughes, TM | 1 |
| George, AS | 1 |
| Hill, CS | 1 |
| Montgomery, SA | 1 |
| Brown, AJ | 1 |
| Bluemling, GR | 1 |
| Natchus, MG | 1 |
| Saindane, M | 1 |
| Kolykhalov, AA | 1 |
| Painter, G | 1 |
| Harcourt, J | 1 |
| Tamin, A | 1 |
| Thornburg, NJ | 1 |
| Swanstrom, R | 1 |
| Denison, MR | 1 |
| Baric, RS | 1 |
| Barlow, A | 1 |
| Landolf, KM | 1 |
| Barlow, B | 1 |
| Yeung, SYA | 1 |
| Heavner, JJ | 1 |
| Claassen, CW | 1 |
| Heavner, MS | 1 |
| Grein, J | 2 |
| Ohmagari, N | 2 |
| Shin, D | 1 |
| Diaz, G | 2 |
| Asperges, E | 1 |
| Castagna, A | 2 |
| Feldt, T | 1 |
| Green, G | 1 |
| Green, ML | 1 |
| Lescure, FX | 2 |
| Nicastri, E | 2 |
| Oda, R | 1 |
| Yo, K | 1 |
| Quiros-Roldan, E | 1 |
| Studemeister, A | 1 |
| Redinski, J | 1 |
| Ahmed, S | 1 |
| Bernett, J | 1 |
| Chelliah, D | 1 |
| Chihara, S | 1 |
| Cohen, SH | 1 |
| Cunningham, J | 1 |
| D'Arminio Monforte, A | 1 |
| Ismail, S | 1 |
| Kato, H | 1 |
| Lapadula, G | 1 |
| L'Her, E | 1 |
| Maeno, T | 1 |
| Majumder, S | 1 |
| Massari, M | 1 |
| Mora-Rillo, M | 1 |
| Mutoh, Y | 1 |
| Nguyen, D | 1 |
| Verweij, E | 1 |
| Zoufaly, A | 1 |
| Osinusi, AO | 3 |
| DeZure, A | 1 |
| Zhao, Y | 2 |
| Zhong, L | 1 |
| Chokkalingam, A | 1 |
| Elboudwarej, E | 1 |
| Telep, L | 1 |
| Timbs, L | 1 |
| Henne, I | 1 |
| Sellers, S | 1 |
| Cao, H | 4 |
| Tan, SK | 1 |
| Winterbourne, L | 1 |
| Desai, P | 1 |
| Mera, R | 1 |
| Gaggar, A | 3 |
| Myers, RP | 2 |
| Brainard, DM | 3 |
| Childs, R | 1 |
| Flanigan, T | 1 |
| Serafin, MB | 1 |
| Bottega, A | 1 |
| Foletto, VS | 1 |
| da Rosa, TF | 1 |
| Hörner, A | 1 |
| Hörner, R | 1 |
| Hillaker, E | 1 |
| Belfer, JJ | 1 |
| Bondici, A | 1 |
| Murad, H | 1 |
| Dumkow, LE | 1 |
| Sanders, JM | 1 |
| Monogue, ML | 1 |
| Jodlowski, TZ | 1 |
| Cutrell, JB | 1 |
| Banerjee, AK | 1 |
| Arora, N | 1 |
| Boyarsky, BJ | 1 |
| Po-Yu Chiang, T | 1 |
| Werbel, WA | 1 |
| Durand, CM | 1 |
| Avery, RK | 1 |
| Getsin, SN | 1 |
| Jackson, KR | 1 |
| Kernodle, AB | 1 |
| Van Pilsum Rasmussen, SE | 1 |
| Massie, AB | 1 |
| Segev, DL | 1 |
| Garonzik-Wang, JM | 1 |
| Shannon, A | 1 |
| Le, NT | 1 |
| Selisko, B | 1 |
| Eydoux, C | 1 |
| Alvarez, K | 1 |
| Guillemot, JC | 1 |
| Decroly, E | 1 |
| Peersen, O | 1 |
| Ferron, F | 1 |
| Canard, B | 1 |
| Şimşek Yavuz, S | 1 |
| Ünal, S | 1 |
| Costanzo, M | 1 |
| De Giglio, MAR | 1 |
| Roviello, GN | 1 |
| Sahu, KK | 1 |
| Mishra, AK | 1 |
| Lal, A | 1 |
| Elens, L | 1 |
| Langman, LJ | 1 |
| Hesselink, DA | 1 |
| Bergan, S | 1 |
| Moes, DJAR | 1 |
| Molinaro, M | 1 |
| Venkataramanan, R | 1 |
| Lemaitre, F | 1 |
| Jogalekar, MP | 1 |
| Veerabathini, A | 1 |
| Gangadaran, P | 1 |
| Jean, SS | 1 |
| Hsu, JJ | 1 |
| Gaynor, P | 1 |
| Kamath, M | 1 |
| Fan, A | 1 |
| Al-Saffar, F | 1 |
| Cruz, D | 1 |
| Nsair, A | 1 |
| Dondorp, AM | 1 |
| Hayat, M | 1 |
| Aryal, D | 1 |
| Beane, A | 1 |
| Schultz, MJ | 1 |
| Li, H | 4 |
| Liu, Z | 2 |
| Ge, J | 2 |
| Ferner, RE | 1 |
| Aronson, JK | 1 |
| Manning, TJ | 1 |
| Thomas-Richardson, J | 1 |
| Cowan, M | 1 |
| Beard, T | 1 |
| Pereira, MR | 1 |
| Mohan, S | 1 |
| Cohen, DJ | 1 |
| Husain, SA | 1 |
| Dube, GK | 1 |
| Ratner, LE | 1 |
| Arcasoy, S | 1 |
| Aversa, MM | 1 |
| Benvenuto, LJ | 1 |
| Dadhania, DM | 1 |
| Kapur, S | 1 |
| Dove, LM | 1 |
| Brown, RS | 1 |
| Rosenblatt, RE | 1 |
| Samstein, B | 1 |
| Uriel, N | 1 |
| Farr, MA | 1 |
| Satlin, M | 1 |
| Small, CB | 1 |
| Walsh, TJ | 1 |
| Kodiyanplakkal, RP | 1 |
| Miko, BA | 1 |
| Aaron, JG | 1 |
| Tsapepas, DS | 1 |
| Emond, JC | 1 |
| Verna, EC | 1 |
| Ledford, H | 4 |
| Augustin, M | 2 |
| Hallek, M | 2 |
| Nitschmann, S | 2 |
| Mehta, N | 1 |
| Mazer-Amirshahi, M | 1 |
| Alkindi, N | 1 |
| Pourmand, A | 1 |
| Ahsan, W | 1 |
| Javed, S | 1 |
| Bratty, MA | 1 |
| Alhazmi, HA | 1 |
| Najmi, A | 1 |
| Ardura, M | 1 |
| Hartley, D | 1 |
| Dandoy, C | 1 |
| Lehmann, L | 1 |
| Jaglowski, S | 1 |
| Auletta, JJ | 1 |
| Su, TH | 1 |
| Kao, JH | 1 |
| Jeevaratnam, K | 1 |
| Ma, Q | 1 |
| Pan, W | 1 |
| Li, R | 1 |
| Liu, B | 2 |
| Li, C | 3 |
| Xie, Y | 1 |
| Wang, Z | 1 |
| Zhao, J | 3 |
| Jiang, H | 1 |
| Huang, J | 1 |
| Shi, Y | 2 |
| Dai, J | 1 |
| Zheng, K | 1 |
| Li, X | 3 |
| Yang, Z | 1 |
| Avataneo, V | 2 |
| de Nicolò, A | 1 |
| Cusato, J | 1 |
| Antonucci, M | 1 |
| Manca, A | 1 |
| Palermiti, A | 1 |
| Waitt, C | 1 |
| Walimbwa, S | 1 |
| Lamorde, M | 1 |
| di Perri, G | 2 |
| D'Avolio, A | 2 |
| Delang, L | 1 |
| Neyts, J | 1 |
| Ballout, RA | 1 |
| Sviridov, D | 1 |
| Bukrinsky, MI | 1 |
| Remaley, AT | 1 |
| Zhou, H | 1 |
| Fang, Y | 1 |
| Xu, T | 1 |
| Ni, WJ | 1 |
| Shen, AZ | 1 |
| Meng, XM | 1 |
| Li, Z | 2 |
| Wang, X | 4 |
| Cao, D | 1 |
| Sun, R | 2 |
| Rubin, EJ | 4 |
| Baden, LR | 4 |
| Morrissey, S | 4 |
| Kiessling, L | 1 |
| MacLaughlin, C | 1 |
| Sattin, S | 1 |
| Douedi, S | 1 |
| Miskoff, J | 1 |
| Coumou, J | 1 |
| de Vries, PJ | 1 |
| Gadebusch Bondio, M | 1 |
| Marloth, M | 1 |
| Anastasiou, IA | 1 |
| Eleftheriadou, I | 1 |
| Tentolouris, A | 1 |
| Tsilingiris, D | 1 |
| Tentolouris, N | 1 |
| Sise, ME | 2 |
| Baggett, MV | 1 |
| Shepard, JO | 1 |
| Stevens, JS | 1 |
| Rhee, EP | 2 |
| Ferguson, J | 1 |
| Rosser, JI | 1 |
| Quintero, O | 1 |
| Scott, J | 1 |
| Subramanian, A | 3 |
| Gumma, M | 1 |
| Rogers, A | 1 |
| Kappagoda, S | 2 |
| Ison, MG | 1 |
| Wolfe, C | 1 |
| Boucher, HW | 1 |
| Chao, JY | 1 |
| Derespina, KR | 1 |
| Herold, BC | 1 |
| Goldman, DL | 1 |
| Aldrich, M | 1 |
| Weingarten, J | 1 |
| Ushay, HM | 1 |
| Cabana, MD | 1 |
| Medar, SS | 1 |
| Antinori, S | 1 |
| Cossu, MV | 1 |
| Ridolfo, AL | 1 |
| Rech, R | 1 |
| Bonazzetti, C | 1 |
| Pagani, G | 1 |
| Gubertini, G | 1 |
| Coen, M | 1 |
| Magni, C | 1 |
| Castelli, A | 1 |
| Borghi, B | 1 |
| Colombo, R | 2 |
| Giorgi, R | 1 |
| Angeli, E | 1 |
| Mileto, D | 1 |
| Milazzo, L | 1 |
| Vimercati, S | 1 |
| Pellicciotta, M | 1 |
| Corbellino, M | 2 |
| Torre, A | 1 |
| Rusconi, S | 1 |
| Oreni, L | 1 |
| Gismondo, MR | 1 |
| Giacomelli, A | 1 |
| Meroni, L | 1 |
| Rizzardini, G | 1 |
| Galli, M | 3 |
| Bonovas, S | 1 |
| Piovani, D | 1 |
| Fätkenheuer, G | 3 |
| Lundgren, J | 4 |
| Hoffmann, C | 1 |
| Wu, J | 2 |
| Wu, B | 1 |
| Lai, T | 1 |
| Brainard, D | 1 |
| Durante-Mangoni, E | 2 |
| Andini, R | 2 |
| Bertolino, L | 2 |
| Mele, F | 2 |
| Florio, LL | 2 |
| Murino, P | 1 |
| Corcione, A | 2 |
| Zampino, R | 2 |
| Nile, SH | 1 |
| Nile, A | 1 |
| Qiu, J | 1 |
| Li, L | 1 |
| Jia, X | 1 |
| Kai, G | 1 |
| Stuebe, A | 1 |
| Franzetti, M | 1 |
| Pozzetti, U | 1 |
| Carugati, M | 1 |
| Pandolfo, A | 1 |
| Molteni, C | 1 |
| Faccioli, P | 1 |
| Castaldo, G | 1 |
| Longoni, E | 1 |
| Ormas, V | 1 |
| Iemoli, E | 1 |
| Piconi, S | 1 |
| Estella, Á | 1 |
| Garnacho-Montero, J | 1 |
| Norrie, JD | 1 |
| Zhang, D | 3 |
| Du, G | 2 |
| Du, R | 2 |
| Jin, Y | 2 |
| Fu, S | 2 |
| Gao, L | 2 |
| Cheng, Z | 2 |
| Lu, Q | 2 |
| Hu, Y | 2 |
| Luo, G | 2 |
| Wang, K | 2 |
| Lu, Y | 2 |
| Wang, S | 2 |
| Ruan, S | 2 |
| Yang, C | 1 |
| Mei, C | 1 |
| Ding, D | 1 |
| Wu, F | 1 |
| Tang, X | 1 |
| Ye, X | 1 |
| Ye, Y | 1 |
| Yang, J | 1 |
| Yin, W | 1 |
| Wang, A | 1 |
| Fan, G | 2 |
| Zhou, F | 2 |
| Gu, X | 2 |
| Xu, J | 2 |
| Shang, L | 1 |
| Zhang, Y | 2 |
| Cao, L | 1 |
| Guo, T | 1 |
| Wan, Y | 1 |
| Qin, H | 1 |
| Jiang, Y | 1 |
| Jaki, T | 2 |
| Hayden, FG | 2 |
| Horby, PW | 2 |
| Cao, B | 3 |
| Wang, C | 4 |
| Marto, N | 1 |
| Monteiro, EC | 1 |
| Aggarwal, G | 1 |
| Henry, BM | 1 |
| Aggarwal, S | 1 |
| Bangalore, S | 1 |
| Cattaneo, D | 2 |
| Gervasoni, C | 2 |
| Riva, A | 1 |
| Clementi, E | 2 |
| Ahmad, SI | 1 |
| Long, B | 1 |
| Liang, SY | 1 |
| Rosenberg, H | 1 |
| Hicks, C | 1 |
| Gottlieb, M | 1 |
| Saha, A | 1 |
| Sharma, AR | 1 |
| Bhattacharya, M | 1 |
| Sharma, G | 1 |
| Lee, SS | 1 |
| Chakraborty, C | 1 |
| Beigel, JH | 2 |
| Tomashek, KM | 2 |
| Dodd, LE | 2 |
| Mehta, AK | 1 |
| Zingman, BS | 1 |
| Kalil, AC | 1 |
| Hohmann, E | 1 |
| Chu, HY | 1 |
| Luetkemeyer, A | 1 |
| Kline, S | 2 |
| Lopez de Castilla, D | 1 |
| Finberg, RW | 1 |
| Dierberg, K | 1 |
| Tapson, V | 1 |
| Hsieh, L | 1 |
| Patterson, TF | 1 |
| Paredes, R | 1 |
| Sweeney, DA | 1 |
| Short, WR | 1 |
| Touloumi, G | 1 |
| Lye, DC | 1 |
| Oh, MD | 2 |
| Ruiz-Palacios, GM | 1 |
| Benfield, T | 1 |
| Kortepeter, MG | 1 |
| Atmar, RL | 1 |
| Creech, CB | 1 |
| Babiker, AG | 1 |
| Pett, S | 1 |
| Neaton, JD | 1 |
| Burgess, TH | 1 |
| Bonnett, T | 1 |
| Green, M | 1 |
| Makowski, M | 1 |
| Osinusi, A | 2 |
| Nayak, S | 1 |
| Lane, HC | 1 |
| Jorgensen, SCJ | 1 |
| Kebriaei, R | 1 |
| Dresser, LD | 1 |
| Liu, Y | 3 |
| Liu, W | 1 |
| Sun, D | 1 |
| Dolin, R | 1 |
| Hirsch, MS | 1 |
| Goldman, JD | 1 |
| Lye, DCB | 1 |
| Hui, DS | 1 |
| Marks, KM | 1 |
| Bruno, R | 1 |
| Montejano, R | 1 |
| Spinner, CD | 2 |
| Ahn, MY | 2 |
| Nahass, RG | 1 |
| Chen, YS | 1 |
| SenGupta, D | 2 |
| Hyland, RH | 2 |
| Blair, C | 2 |
| Wei, X | 1 |
| Towner, WJ | 1 |
| Muñoz, J | 1 |
| Mullane, KM | 2 |
| Marty, FM | 2 |
| Tashima, KT | 1 |
| Davies, M | 1 |
| Osborne, V | 1 |
| Lane, S | 1 |
| Roy, D | 1 |
| Dhanda, S | 1 |
| Evans, A | 1 |
| Shakir, S | 1 |
| Mansuri, Z | 1 |
| Shah, B | 1 |
| Zafar, MK | 1 |
| Jolly, T | 1 |
| Jain, S | 1 |
| Sia, CH | 1 |
| Ngiam, JN | 1 |
| Chew, N | 1 |
| Beh, DLL | 1 |
| Poh, KK | 1 |
| Prajapati, S | 1 |
| Sharma, M | 1 |
| Kumar, A | 1 |
| Gupta, P | 1 |
| Narasimha Kumar, GV | 1 |
| Lang, JP | 1 |
| Moura, FA | 1 |
| Siddiqi, HK | 1 |
| Morrow, DA | 1 |
| Bohula, EA | 1 |
| Gouveia, CC | 1 |
| Campos, L | 1 |
| Maharaj, AR | 1 |
| Wu, H | 1 |
| Hornik, CP | 1 |
| Balevic, SJ | 1 |
| Hornik, CD | 1 |
| Smith, PB | 1 |
| Gonzalez, D | 1 |
| Zimmerman, KO | 1 |
| Benjamin, DK | 1 |
| Cohen-Wolkowiez, M | 1 |
| Andreou, A | 1 |
| Trantza, S | 1 |
| Filippou, D | 1 |
| Sipsas, N | 1 |
| Tsiodras, S | 1 |
| Bimonte, S | 1 |
| Crispo, A | 1 |
| Amore, A | 1 |
| Celentano, E | 1 |
| Cuomo, A | 1 |
| Cascella, M | 1 |
| Gebrie, D | 1 |
| Getnet, D | 1 |
| Manyazewal, T | 1 |
| Nasir, M | 1 |
| Talha, KA | 1 |
| Islam, T | 1 |
| Saha, SK | 1 |
| Selina, F | 1 |
| Parveen, RA | 1 |
| Adamsick, ML | 1 |
| Gandhi, RG | 1 |
| Bidell, MR | 1 |
| Elshaboury, RH | 1 |
| Bhattacharyya, RP | 1 |
| Kim, AY | 1 |
| Nigwekar, S | 1 |
| Benfiels, T | 1 |
| Jensen, TØ | 1 |
| Johansen, IS | 1 |
| Nielsen, H | 1 |
| Wiese, L | 1 |
| Østergaard, L | 1 |
| Williamson, BN | 1 |
| Schwarz, B | 1 |
| Meade-White, K | 1 |
| Porter, DP | 1 |
| Schulz, J | 1 |
| van Doremalen, N | 1 |
| Leighton, I | 1 |
| Yinda, CK | 1 |
| Pérez-Pérez, L | 1 |
| Lovaglio, J | 1 |
| Hanley, PW | 1 |
| Saturday, G | 1 |
| Bosio, CM | 1 |
| Anzick, S | 1 |
| Barbian, K | 1 |
| Martens, C | 1 |
| Scott, DP | 1 |
| Munster, VJ | 1 |
| Fumeaux, T | 1 |
| Segar, S | 1 |
| Bouland, D | 1 |
| Torriani, F | 1 |
| Kwak, K | 1 |
| Asudani, D | 1 |
| Taplitz, R | 1 |
| Gupta, V | 1 |
| Pan, X | 1 |
| Yang, L | 1 |
| Peng, C | 1 |
| Yoo, JH | 1 |
| Frauenfelder, C | 1 |
| Brierley, J | 2 |
| Whittaker, E | 1 |
| Perucca, G | 1 |
| Bamford, A | 2 |
| Di Pasquale, G | 1 |
| Maggioni, AP | 1 |
| Abrams-Downey, A | 1 |
| Saabiye, J | 1 |
| Vidaurrazaga, M | 1 |
| Liang, C | 1 |
| Tian, L | 1 |
| Hui, N | 1 |
| Qiao, G | 1 |
| Tang, Y | 1 |
| Xie, X | 1 |
| Zhao, X | 2 |
| Ahn, BY | 1 |
| Kang, CK | 1 |
| Seo, JD | 1 |
| Choe, PG | 1 |
| Song, SH | 1 |
| Park, WB | 1 |
| Park, SW | 1 |
| Kim, NJ | 1 |
| Lipworth, B | 1 |
| Kuo, CR | 1 |
| Chan, R | 1 |
| Thalha, AMM | 1 |
| Lee, YY | 1 |
| Besari, A | 1 |
| Omar, SFS | 1 |
| Magro, G | 1 |
| Alvarez, JC | 1 |
| Moine, P | 1 |
| Etting, I | 1 |
| Annane, D | 1 |
| Larabi, IA | 1 |
| Timerbulatov, SV | 1 |
| Timerbulstov, MV | 1 |
| Gainullina, EN | 1 |
| Gafarova, AR | 1 |
| Timerbulatov, VM | 1 |
| White, DB | 1 |
| Angus, DC | 2 |
| Sarpatwari, A | 1 |
| Kaltenboeck, A | 1 |
| Kesselheim, AS | 1 |
| Daunt, A | 1 |
| Perez-Guzman, PN | 1 |
| Liew, F | 1 |
| Hauck, K | 1 |
| Costelloe, CE | 1 |
| Thursz, MR | 1 |
| Cooke, G | 1 |
| Nayagam, S | 1 |
| Humeniuk, R | 1 |
| Mathias, A | 1 |
| Shen, G | 1 |
| Chng, E | 1 |
| Ling, J | 1 |
| Vu, A | 1 |
| German, P | 1 |
| Adachi, E | 1 |
| Saito, M | 1 |
| Ikeuchi, K | 1 |
| Hoshina, T | 1 |
| Yotsuyanagi, H | 1 |
| Wang, L | 1 |
| Ren, L | 1 |
| Brandt, N | 1 |
| Chou, J | 1 |
| Nittari, G | 1 |
| Pallotta, G | 1 |
| Amenta, F | 1 |
| Tayebati, SK | 1 |
| Tempestilli, M | 1 |
| Caputi, P | 1 |
| Notari, S | 1 |
| Forini, O | 1 |
| Scorzolini, L | 1 |
| Marchioni, L | 1 |
| Ascoli Bartoli, T | 1 |
| Castilletti, C | 1 |
| Lalle, E | 1 |
| Capobianchi, MR | 1 |
| Ippolito, G | 1 |
| Agrati, C | 1 |
| Varghese, GM | 1 |
| John, R | 1 |
| Manesh, A | 1 |
| Karthik, R | 1 |
| Abraham, OC | 1 |
| Khan, A | 1 |
| Khan, M | 2 |
| Saleem, S | 1 |
| Babar, Z | 1 |
| Ali, A | 1 |
| Khan, AA | 1 |
| Sardar, Z | 1 |
| Hamayun, F | 1 |
| Ali, SS | 1 |
| Wei, DQ | 1 |
| Naqvi, M | 1 |
| Zakowski, P | 1 |
| Glucksman, L | 1 |
| Smithson, S | 1 |
| Burwick, RM | 1 |
| Dubert, M | 1 |
| Visseaux, B | 2 |
| Isernia, V | 1 |
| Bouadma, L | 1 |
| Deconinck, L | 1 |
| Patrier, J | 1 |
| Wicky, PH | 2 |
| Le Pluart, D | 1 |
| Kramer, L | 1 |
| Rioux, C | 1 |
| Le Hingrat, Q | 2 |
| Houhou-Fidouh, N | 1 |
| Yazdanpanah, Y | 1 |
| Ghosn, J | 1 |
| Azmy, V | 1 |
| Benson, J | 1 |
| Love, K | 1 |
| Steele, R | 1 |
| Hosoki, K | 1 |
| Chakraborty, A | 1 |
| Sur, S | 1 |
| Danta, CC | 1 |
| Agostinis, P | 1 |
| Rabson, A | 1 |
| Melino, G | 1 |
| Carafoli, E | 1 |
| Sun, E | 1 |
| Giovane, RA | 1 |
| Rezai, S | 1 |
| Cleland, E | 1 |
| Henderson, CE | 1 |
| Gillenwater, S | 1 |
| Rahaghi, F | 1 |
| Hadeh, A | 1 |
| McMahon, JH | 1 |
| Udy, A | 1 |
| Peleg, AY | 1 |
| McCaw, ZR | 1 |
| Kim, DH | 1 |
| Wei, LJ | 1 |
| Olalla, J | 1 |
| Orf, K | 1 |
| Rogosic, S | 1 |
| Dexter, D | 1 |
| Ancliff, P | 1 |
| Badle, S | 1 |
| Cheng, D | 1 |
| Dalton, C | 1 |
| Dixon, G | 1 |
| Du Pré, P | 1 |
| Grandjean, L | 1 |
| Ghorashian, S | 1 |
| Mittal, P | 1 |
| O'Connor, D | 1 |
| Pavasovic, V | 1 |
| Rao, A | 1 |
| Samarasinghe, S | 1 |
| Vora, A | 1 |
| Bartram, J | 1 |
| Kouzy, R | 1 |
| Abi Jaoude, J | 1 |
| Garcia Garcia, CJ | 1 |
| El Alam, MB | 1 |
| Taniguchi, CM | 1 |
| Ludmir, EB | 1 |
| Bakare, LS | 1 |
| Allen, JM | 1 |
| Marouf, BH | 1 |
| Dizaye, K | 1 |
| Pizzorno, A | 1 |
| Padey, B | 1 |
| Dubois, J | 1 |
| Julien, T | 1 |
| Traversier, A | 1 |
| Dulière, V | 1 |
| Brun, P | 1 |
| Lina, B | 1 |
| Rosa-Calatrava, M | 1 |
| Terrier, O | 1 |
| Wang, D | 1 |
| Paladugu, S | 1 |
| Donato, AA | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Azevedo, TCP | 1 |
| Azevedo, PCP | 1 |
| Silveira Filho, RN | 1 |
| Carvalho, ARVS | 1 |
| Cezarotti Filho, ML | 1 |
| Barbosa, FT | 1 |
| Sousa-Rodrigues, CF | 1 |
| Matos-Rocha, TJ | 1 |
| Ramos, FWDS | 1 |
| Rivera, DR | 1 |
| Peters, S | 1 |
| Panagiotou, OA | 1 |
| Shah, DP | 1 |
| Kuderer, NM | 1 |
| Hsu, CY | 1 |
| Rubinstein, SM | 1 |
| Lee, BJ | 1 |
| Choueiri, TK | 1 |
| de Lima Lopes, G | 1 |
| Grivas, P | 1 |
| Painter, CA | 1 |
| Rini, BI | 1 |
| Thompson, MA | 1 |
| Arcobello, J | 1 |
| Bakouny, Z | 1 |
| Doroshow, DB | 1 |
| Egan, PC | 1 |
| Farmakiotis, D | 1 |
| Fecher, LA | 1 |
| Friese, CR | 1 |
| Galsky, MD | 1 |
| Goel, S | 1 |
| Gupta, S | 2 |
| Halfdanarson, TR | 1 |
| Halmos, B | 1 |
| Hawley, JE | 1 |
| Khaki, AR | 1 |
| Lemmon, CA | 1 |
| Mishra, S | 1 |
| Olszewski, AJ | 1 |
| Pennell, NA | 1 |
| Puc, MM | 1 |
| Revankar, SG | 1 |
| Schapira, L | 1 |
| Schmidt, A | 1 |
| Schwartz, GK | 1 |
| Shah, SA | 1 |
| Wu, JT | 1 |
| Xie, Z | 1 |
| Yeh, AC | 1 |
| Zhu, H | 1 |
| Shyr, Y | 1 |
| Lyman, GH | 1 |
| Warner, JL | 1 |
| Helleberg, M | 1 |
| Niemann, CU | 1 |
| Moestrup, KS | 1 |
| Kirk, O | 1 |
| Lebech, AM | 1 |
| Lane, C | 1 |
| Riva, L | 1 |
| Yuan, S | 1 |
| Yin, X | 1 |
| Martin-Sancho, L | 1 |
| Matsunaga, N | 1 |
| Pache, L | 1 |
| Burgstaller-Muehlbacher, S | 1 |
| De Jesus, PD | 1 |
| Teriete, P | 1 |
| Hull, MV | 1 |
| Chang, MW | 1 |
| Chan, JF | 1 |
| Cao, J | 1 |
| Poon, VK | 1 |
| Herbert, KM | 1 |
| Cheng, K | 1 |
| Nguyen, TH | 1 |
| Rubanov, A | 1 |
| Pu, Y | 1 |
| Nguyen, C | 1 |
| Choi, A | 1 |
| Rathnasinghe, R | 1 |
| Schotsaert, M | 1 |
| Miorin, L | 1 |
| Dejosez, M | 1 |
| Zwaka, TP | 1 |
| Sit, KY | 1 |
| Martinez-Sobrido, L | 1 |
| Liu, WC | 1 |
| White, KM | 1 |
| Chapman, ME | 1 |
| Lendy, EK | 1 |
| Glynne, RJ | 1 |
| Albrecht, R | 1 |
| Ruppin, E | 1 |
| Mesecar, AD | 1 |
| Johnson, JR | 1 |
| Benner, C | 1 |
| Schultz, PG | 1 |
| Su, AI | 1 |
| García-Sastre, A | 1 |
| Chatterjee, AK | 1 |
| Yuen, KY | 1 |
| Chanda, SK | 1 |
| Manjaly Thomas, ZR | 1 |
| Leuppi-Taegtmeyer, A | 1 |
| Jamiolkowski, D | 1 |
| Steveling-Klein, E | 1 |
| Bellutti-Enders, F | 1 |
| Scherer Hofmeier, K | 1 |
| Hartmann, K | 1 |
| Silva Arouche, TD | 1 |
| Reis, AF | 1 |
| Martins, AY | 1 |
| S Costa, JF | 1 |
| Carvalho Junior, RN | 1 |
| J C Neto, AM | 1 |
| Montastruc, F | 1 |
| Thuriot, S | 1 |
| Durrieu, G | 1 |
| Abd Ellah, NH | 1 |
| Gad, SF | 1 |
| Muhammad, K | 1 |
| E Batiha, G | 1 |
| Hetta, HF | 1 |
| Galdo, M | 1 |
| De Rosa, R | 1 |
| Musa, A | 1 |
| Pendi, K | 1 |
| Hashemi, A | 1 |
| Warbasse, E | 1 |
| Kouyoumjian, S | 1 |
| Yousif, J | 1 |
| Blodget, E | 1 |
| Stevens, S | 1 |
| Aly, B | 1 |
| Baron, DA | 1 |
| Téllez, L | 1 |
| Martín Mateos, RM | 1 |
| Weckbach, LT | 1 |
| Kellnar, A | 1 |
| Stremmel, C | 1 |
| Stark, K | 1 |
| Kääb, S | 1 |
| Siemieniuk, RA | 1 |
| Bartoszko, JJ | 1 |
| Zeraatkar, D | 2 |
| Kum, E | 1 |
| Qasim, A | 1 |
| Martinez, JPD | 1 |
| Izcovich, A | 1 |
| Lamontagne, F | 2 |
| Han, MA | 1 |
| Agarwal, A | 2 |
| Agoritsas, T | 2 |
| Azab, M | 1 |
| Bravo, G | 1 |
| Chu, DK | 1 |
| Couban, R | 1 |
| Devji, T | 1 |
| Escamilla, Z | 1 |
| Foroutan, F | 1 |
| Gao, Y | 1 |
| Ge, L | 2 |
| Ghadimi, M | 1 |
| Heels-Ansdell, D | 1 |
| Honarmand, K | 1 |
| Hou, L | 1 |
| Ibrahim, Q | 1 |
| Khamis, A | 1 |
| Lam, B | 1 |
| Mansilla, C | 1 |
| Loeb, M | 1 |
| Miroshnychenko, A | 1 |
| Marcucci, M | 1 |
| McLeod, SL | 1 |
| Motaghi, S | 1 |
| Murthy, S | 2 |
| Mustafa, RA | 1 |
| Pardo-Hernandez, H | 1 |
| Rada, G | 1 |
| Rizwan, Y | 1 |
| Saadat, P | 1 |
| Switzer, C | 1 |
| Thabane, L | 1 |
| Tomlinson, G | 1 |
| Vandvik, PO | 2 |
| Vernooij, RW | 1 |
| Viteri-García, A | 1 |
| Yao, L | 1 |
| Guyatt, GH | 1 |
| Brignardello-Petersen, R | 2 |
| Rochwerg, B | 1 |
| Zeng, L | 1 |
| Leo, YS | 1 |
| Appiah, JA | 1 |
| Bartoszko, J | 1 |
| Ergan, B | 1 |
| Geduld, H | 1 |
| Gershengorn, HB | 1 |
| Manai, H | 1 |
| Huang, M | 1 |
| Kanda, S | 1 |
| Kawano-Dourado, L | 1 |
| Kurian, L | 1 |
| Kwizera, A | 1 |
| Qadir, N | 1 |
| Siemieniuk, R | 1 |
| Silvestre, MA | 1 |
| Ye, Z | 1 |
| Guyatt, G | 1 |
| Saitz, R | 1 |
| Schwitzer, G | 1 |
| Wang, J | 2 |
| Shuai, L | 1 |
| Liu, R | 1 |
| He, X | 1 |
| Zhang, X | 1 |
| Sun, Z | 1 |
| Shan, D | 1 |
| Hua, R | 1 |
| Zhong, G | 1 |
| Wen, Z | 1 |
| Bu, Z | 1 |
| Baombe, JP | 1 |
| Mendes, A | 1 |
| Yu, X | 1 |
| Li, N | 1 |
| Li, Y | 2 |
| Miao, H | 1 |
| Yao, Y | 1 |
| Wu, M | 1 |
| Lu, C | 1 |
| Tian, M | 1 |
| Luo, P | 1 |
| Gu, J | 1 |
| Yuan, B | 1 |
| Gan, W | 1 |
| Zhao, D | 1 |
| Igbinosa, I | 1 |
| Miller, S | 1 |
| Bianco, K | 1 |
| Nelson, J | 1 |
| Blackburn, BG | 1 |
| Grant, P | 1 |
| Lyell, DJ | 1 |
| El-Sayed, YY | 1 |
| Aziz, N | 1 |
| Jomah, S | 1 |
| Asdaq, SMB | 1 |
| Al-Yamani, MJ | 1 |
| Shamim, S | 1 |
| Kharaba, ZJ | 1 |
| Ijaz, M | 1 |
| Murtaza, G | 1 |
| Hazard, D | 1 |
| Kaier, K | 1 |
| von Cube, M | 1 |
| Grodd, M | 1 |
| Bugiera, L | 1 |
| Lambert, J | 1 |
| Wolkewitz, M | 1 |
| Bigley, AN | 1 |
| Narindoshvili, T | 1 |
| Raushel, FM | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Gonzalez-Gay, MA | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Alvaro-Gracia, JM | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Chua, KP | 1 |
| Conti, RM | 1 |
| Bonardel, C | 1 |
| Bonnerot, M | 1 |
| Ludwig, M | 1 |
| Vadot, W | 1 |
| Beaune, G | 1 |
| Chanzy, B | 1 |
| Cornut, L | 1 |
| Baysson, H | 1 |
| Farines, M | 1 |
| Combes, I | 1 |
| Macheda, G | 1 |
| Bing, F | 1 |
| Misra, S | 1 |
| Nath, M | 1 |
| Hadda, V | 1 |
| Vibha, D | 1 |
| Hashemian, SM | 1 |
| Farhadi, T | 1 |
| Velayati, AA | 1 |
| McCreary, EK | 1 |
| Gottlieb, RL | 1 |
| Criner, GJ | 1 |
| Arribas López, JR | 1 |
| Cattelan, AM | 1 |
| Soriano Viladomiu, A | 1 |
| Ogbuagu, O | 1 |
| Malhotra, P | 1 |
| Chai, LYA | 1 |
| Roestenberg, M | 1 |
| Tsang, OTY | 1 |
| Bernasconi, E | 1 |
| Le Turnier, P | 1 |
| Chang, SC | 1 |
| Wang, H | 1 |
| McPhail, MJ | 1 |
| Bhagani, S | 2 |
| Sanyal, AJ | 1 |
| Huhn, G | 1 |
| Yokoyama, Y | 1 |
| Briasoulis, A | 1 |
| Takagi, H | 1 |
| Kuno, T | 1 |
| Pasquini, Z | 1 |
| Montalti, R | 1 |
| Temperoni, C | 1 |
| Canovari, B | 1 |
| Mancini, M | 1 |
| Tempesta, M | 1 |
| Pimpini, D | 1 |
| Zallocco, N | 1 |
| Barchiesi, F | 1 |
| Weber, E | 1 |
| Bliton, MJ | 1 |
| Fadaka, AO | 1 |
| Sibuyi, NRS | 1 |
| Adewale, OB | 1 |
| Bakare, OO | 1 |
| Akanbi, MO | 1 |
| Klein, A | 1 |
| Madiehe, AM | 1 |
| Meyer, M | 1 |
| Robson, F | 1 |
| Khan, KS | 1 |
| Le, TK | 1 |
| Paris, C | 1 |
| Demirbag, S | 1 |
| Barfuss, P | 1 |
| Rocchi, P | 1 |
| Ng, WL | 1 |
| Lim, S | 1 |
| DeBruin, DA | 1 |
| Leider, JP | 1 |
| Sederstrom, N | 1 |
| Lynfield, R | 1 |
| Baker, JV | 1 |
| Kesler, S | 1 |
| Rizza, S | 1 |
| Sharp, RR | 1 |
| Wolf, SM | 1 |
| Uzunova, K | 1 |
| Filipova, E | 1 |
| Pavlova, V | 1 |
| Vekov, T | 1 |
| Richardson, C | 1 |
| Pollara, G | 1 |
| Shih, WJ | 1 |
| Yao, C | 1 |
| Xie, T | 1 |
| Lê, MP | 1 |
| Jaquet, P | 1 |
| Bunel, V | 1 |
| Massias, L | 1 |
| Messika, J | 1 |
| Descamps, D | 1 |
| Mal, H | 1 |
| Timsit, JF | 1 |
| Peytavin, G | 1 |
| Lamb, YN | 1 |
| Kay, AW | 1 |
| Ness, TE | 1 |
| Martinez, L | 1 |
| Mandalakas, AM | 1 |
| Gonzales-Zamora, JA | 1 |
| Quiroz, T | 1 |
| Vega, AD | 1 |
| Green, RJ | 1 |
| Mustafa, F | 1 |
| Sewlall, N | 1 |
| Richards, GA | 1 |
| Dobrovolny, HM | 1 |
| Doggrell, SA | 1 |
| Merhi, B | 1 |
| Gohh, R | 1 |
| Saint-Raymond, A | 1 |
| Sato, J | 1 |
| Kishioka, Y | 1 |
| Teixeira, T | 1 |
| Hasslboeck, C | 1 |
| Kweder, SL | 1 |
| Rodriguez, Z | 1 |
| Shane, AL | 1 |
| Verkerke, H | 1 |
| Lough, C | 1 |
| Zimmerman, MG | 1 |
| Suthar, M | 1 |
| Wrammert, J | 1 |
| MacDonald, H | 1 |
| Wolf, M | 1 |
| Clarke, S | 1 |
| Roback, JD | 1 |
| Arthur, CM | 1 |
| Stowell, SR | 1 |
| Josephson, CD | 1 |
| Shilatifard, A | 1 |
| Rasmussen, HB | 1 |
| Hansen, PR | 1 |
| Taboureau, O | 1 |
| Thomsen, R | 1 |
| Jürgens, G | 1 |
| Ader, F | 1 |
| Gupta, SP | 1 |
| Alshaeri, HK | 1 |
| Natto, ZS | 1 |
| Bai, YX | 1 |
| Xu, YH | 1 |
| Sun, C | 1 |
| Guo, Y | 1 |
| Qiu, S | 1 |
| Ma, KW | 1 |
| Perišić, O | 1 |
| Roberto, P | 1 |
| Francesco, L | 1 |
| Emanuela, C | 1 |
| Giorgia, G | 1 |
| Pasquale, N | 1 |
| Sara, D | 1 |
| Dzhafer, N | 1 |
| Papathanasiou, JV | 1 |
| Glaus, MJ | 1 |
| Von Ruden, S | 1 |
| Edwards, JK | 1 |
| Cole, SR | 1 |
| Adimora, AA | 1 |
| Wang, LY | 1 |
| Cui, JJ | 1 |
| Ouyang, QY | 1 |
| Zhan, Y | 1 |
| Guo, CX | 1 |
| Yin, JY | 1 |
| Gómez-Moreno, G | 1 |
| Jockusch, S | 1 |
| Tao, C | 1 |
| Chien, M | 1 |
| Kumar, S | 1 |
| Morozova, I | 1 |
| Kalachikov, S | 1 |
| Russo, JJ | 1 |
| Ju, J | 1 |
| Schwartz, RA | 1 |
| Sharma, A | 1 |
| Szepietowski, JC | 1 |
| Sandhu, S | 1 |
| Goldust, M | 1 |
| Malin, JJ | 1 |
| Suárez, I | 1 |
| Priesner, V | 1 |
| Rybniker, J | 1 |
| Kaushik, A | 1 |
| Gupta, J | 1 |
| Knapp, RR | 1 |
| Tona, V | 1 |
| Okada, T | 1 |
| Sarpong, R | 1 |
| Garg, NK | 1 |
| Maveddat, A | 1 |
| Mallah, H | 1 |
| Rao, S | 1 |
| Ali, K | 1 |
| Sherali, S | 1 |
| Nugent, K | 1 |
| Singh, PK | 1 |
| Pathania, S | 1 |
| Rawal, RK | 1 |
| Khalaf, K | 1 |
| Papp, N | 1 |
| Chou, JT | 1 |
| Hana, D | 1 |
| Mackiewicz, A | 1 |
| Kaczmarek, M | 1 |
| Sabers, AJ | 1 |
| Williams, AL | 1 |
| Farley, TM | 1 |
| Daoud, S | 1 |
| Alabed, SJ | 1 |
| Dahabiyeh, LA | 1 |
| Niburski, K | 1 |
| Niburski, O | 1 |
| Pandolfi, L | 1 |
| Fossali, T | 1 |
| Frangipane, V | 1 |
| Bozzini, S | 1 |
| Morosini, M | 1 |
| D'Amato, M | 1 |
| Lettieri, S | 1 |
| Urtis, M | 1 |
| Di Toro, A | 1 |
| Saracino, L | 1 |
| Percivalle, E | 1 |
| Tomaselli, S | 1 |
| Cavagna, L | 1 |
| Cova, E | 1 |
| Mojoli, F | 1 |
| Bergomi, P | 1 |
| Ottolina, D | 1 |
| Lilleri, D | 1 |
| Corsico, AG | 1 |
| Arbustini, E | 1 |
| Meloni, F | 1 |
| Chen, CH | 1 |
| Pan, MY | 1 |
| Liu, HY | 1 |
| Hopwood, AJ | 1 |
| Jordan-Villegas, A | 1 |
| Gutierrez, LD | 1 |
| Cowart, MC | 1 |
| Vega-Montalvo, W | 1 |
| Cheung, WL | 1 |
| McMahan, MJ | 1 |
| Gomez, MR | 1 |
| Laham, FR | 1 |
| Trkulja, V | 1 |
| Qaseem, A | 1 |
| Yost, J | 1 |
| Etxeandia-Ikobaltzeta, I | 1 |
| Abraham, GM | 1 |
| Jokela, JA | 1 |
| Forciea, MA | 1 |
| Miller, MC | 1 |
| Humphrey, LL | 1 |
| Centor, RM | 1 |
| Andrews, R | 1 |
| Haeme, R | 1 |
| Kaka, AS | 1 |
| MacDonald, R | 1 |
| Greer, N | 1 |
| Vela, K | 1 |
| Duan-Porter, W | 1 |
| Obley, A | 1 |
| Wilt, TJ | 1 |
| Bhagavan, SM | 1 |
| Ramaswamy, SB | 1 |
| Govindarajan, R | 1 |
| Furlan, A | 1 |
| Forner, G | 1 |
| Cipriani, L | 1 |
| Vian, E | 1 |
| Rigoli, R | 1 |
| Gherlinzoni, F | 1 |
| Scotton, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial[NCT04405310] | Phase 2 | 42 participants (Actual) | Interventional | 2020-05-20 | Completed | ||
| Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia[NCT04358783] | Phase 2 | 31 participants (Actual) | Interventional | 2020-04-27 | Completed | ||
| Efficacy and Safety of Sirolimus for Treating COVID-19 Infection[NCT04461340] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-08-15 | Recruiting | ||
| Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma[NCT04432103] | Phase 3 | 6 participants (Actual) | Interventional | 2020-08-08 | Terminated (stopped due to There is new evidence that the Convalescent plasma is not useful for severe and critical COVID-19 Pneumonia) | ||
| Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628] | Phase 2 | 452 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial[NCT04339816] | Phase 3 | 3 participants (Actual) | Interventional | 2020-05-13 | Terminated (stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data) | ||
| Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial[NCT04359095] | Phase 2/Phase 3 | 650 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467] | Phase 2 | 3,217 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial[NCT04596839] | Phase 2 | 60 participants (Actual) | Interventional | 2020-09-04 | Completed | ||
| Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260] | 152 participants (Actual) | Interventional | 2021-03-18 | Completed | |||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.[NCT04365725] | 84 participants (Actual) | Observational | 2020-05-05 | Completed | |||
| An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -[NCT04600999] | Phase 3 | 14 participants (Actual) | Interventional | 2020-10-07 | Completed | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study[NCT04380870] | 500 participants (Anticipated) | Observational | 2020-05-11 | Recruiting | |||
| A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization[NCT04365582] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-07 | Withdrawn (stopped due to The PI decided.) | ||
| Impact of Colchicine in Hospitalized Colombian Patients With COVID-19[NCT04539873] | Phase 3 | 128 participants (Actual) | Interventional | 2021-04-30 | Terminated (stopped due to non-inclusion of patients in the study effectively) | ||
| Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19[NCT04349592] | 456 participants (Actual) | Interventional | 2020-04-14 | Completed | |||
| Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study[NCT04463264] | Phase 2/Phase 3 | 135 participants (Anticipated) | Interventional | 2020-06-26 | Recruiting | ||
| Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial[NCT04345289] | Phase 3 | 147 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to DSMB advise due to high probability of futility) | ||
| The Role of the Bacillus Calmette-Guérin Vaccine (BCG) in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) Vaccines[NCT05507671] | Phase 3 | 556 participants (Anticipated) | Interventional | 2021-05-27 | Active, not recruiting | ||
| A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting[NCT04370782] | Phase 4 | 18 participants (Actual) | Interventional | 2020-04-28 | Completed | ||
| Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh[NCT04402203] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2020-05-31 | Recruiting | ||
| Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019] | Phase 2/Phase 3 | 1,930 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia[NCT04654416] | 301 participants (Actual) | Observational | 2020-03-20 | Completed | |||
| Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients[NCT04610541] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2020-10-12 | Active, not recruiting | ||
| Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)[NCT04361526] | 40 participants (Anticipated) | Interventional | 2020-04-17 | Recruiting | |||
| MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719] | 200 participants (Anticipated) | Interventional | 2020-11-08 | Recruiting | |||
| The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY[NCT04705766] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2021-03-01 | Recruiting | |||
| Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial[NCT04519125] | Phase 2/Phase 3 | 950 participants (Anticipated) | Interventional | 2020-08-30 | Not yet recruiting | ||
| Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)[NCT04405271] | Phase 3 | 1,378 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356] | 120 participants (Actual) | Observational | 2020-11-19 | Completed | |||
| Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection[NCT04326036] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2020-03-25 | Enrolling by invitation | ||
| "Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament ACAR en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes"[NCT04501965] | Phase 2 | 231 participants (Actual) | Interventional | 2020-06-01 | Enrolling by invitation | ||
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts[NCT04652648] | Phase 4 | 54 participants (Actual) | Interventional | 2020-05-27 | Completed | ||
| Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study[NCT04326725] | 80 participants (Anticipated) | Observational | 2020-03-20 | Active, not recruiting | |||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications[NCT04502342] | Phase 2 | 30 participants (Actual) | Interventional | 2020-06-01 | Enrolling by invitation | ||
| Computed Tomography for Coronavirus Disease 19 Diagnosis[NCT04355507] | 10,735 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial[NCT04387760] | Phase 2 | 150 participants (Actual) | Interventional | 2020-08-11 | Completed | ||
| Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial[NCT04356534] | 40 participants (Actual) | Interventional | 2020-04-19 | Completed | |||
| Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study[NCT04375709] | 60 participants (Anticipated) | Observational | 2020-03-15 | Recruiting | |||
| Viral Kinetics of SARS-CoV-2 in Patients in the Intensive Care Unit Undergoing Dental Procedures[NCT05311410] | 60 participants (Anticipated) | Interventional | 2021-09-20 | Recruiting | |||
| Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19[NCT05132972] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2021-01-17 | Recruiting | ||
| Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients[NCT04437823] | Phase 2 | 5 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic[NCT04540926] | Phase 1/Phase 2 | 200 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm[NCT04355247] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-04-14 | Recruiting | ||
| Clinical Characteristics and Outcomes of 187 Critically Ill Patients With COVID-19[NCT04454372] | 187 participants (Actual) | Observational | 2020-07-15 | Completed | |||
| Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial[NCT04377503] | Phase 2 | 30 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to The number of critically ill patients wirh COVID-19 decrease abruptly) | ||
| Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
| The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial[NCT04392713] | 100 participants (Anticipated) | Interventional | 2020-04-15 | Recruiting | |||
| Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.[NCT05045937] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2022-05-01 | Recruiting | |||
| Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled[NCT04529525] | Phase 2/Phase 3 | 501 participants (Actual) | Interventional | 2020-08-19 | Completed | ||
| Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients[NCT04472585] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2020-11-14 | Recruiting | ||
| Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Therapeutic Safety of Ivermectin Versus Placebo Associated With Standard of Care Treatment in the Early Phase of Coronavirus Infection (COVID19).[NCT04836299] | Phase 2 | 90 participants (Anticipated) | Interventional | 2021-05-08 | Not yet recruiting | ||
| The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management[NCT04646109] | Phase 3 | 66 participants (Actual) | Interventional | 2020-05-11 | Completed | ||
| Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection[NCT04513158] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | ||
| Evaluation of Awake Prone Positioning Effectiveness in Moderate to Severe COVID-19[NCT05083130] | 93 participants (Actual) | Interventional | 2022-03-08 | Completed | |||
| Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients[NCT05116748] | 200 participants (Anticipated) | Observational | 2021-10-01 | Active, not recruiting | |||
| Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study[NCT04560231] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children[NCT05381363] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2022-01-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease[NCT04533347] | Phase 2 | 86 participants (Actual) | Interventional | 2021-02-19 | Completed | ||
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.[NCT04257656] | Phase 3 | 237 participants (Actual) | Interventional | 2020-02-06 | Terminated (stopped due to The epidemic of COVID-19 has been controlled well in China, no eligible patients can be enrolled at present.) | ||
| A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19[NCT04724720] | Phase 2 | 56 participants (Actual) | Interventional | 2021-01-19 | Active, not recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus[NCT04970719] | Phase 3 | 382 participants (Anticipated) | Interventional | 2021-07-10 | Recruiting | ||
| An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection[NCT04494399] | Phase 2 | 96 participants (Anticipated) | Interventional | 2020-07-29 | Recruiting | ||
| Determination of SARS-CoV2 Antibody Prevalence in Pediatric Patients[NCT04581148] | 7,000 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| An Open-label Randomized Controlled Trial on Interferon β-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection[NCT04647695] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-11-20 | Recruiting | ||
| The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases: a Randomized Double Blind Placebo Controlled Trial[NCT04551755] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults[NCT04280705] | Phase 3 | 1,062 participants (Actual) | Interventional | 2020-02-21 | Completed | ||
| Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19[NCT04492501] | 600 participants (Actual) | Interventional | 2020-04-01 | Completed | |||
| A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection[NCT06008860] | Phase 4 | 280 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial[NCT04894617] | Phase 3 | 226 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| Phase I, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) in Adult Patients With Mild COVID-19[NCT04514302] | Phase 1 | 32 participants (Actual) | Interventional | 2021-12-07 | Completed | ||
| An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection[NCT04465695] | Phase 2 | 81 participants (Anticipated) | Interventional | 2020-07-14 | Recruiting | ||
| A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19[NCT04292899] | Phase 3 | 4,891 participants (Actual) | Interventional | 2020-03-06 | Completed | ||
| First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer[NCT04859244] | Phase 1 | 1 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| "Conducting Clinical Trials of the Medicine Rutan Tablets 0.1g No. 10 in the Complex Therapy of the Viral Disease COVID-19"[NCT05859919] | Phase 2 | 57 participants (Actual) | Interventional | 2020-10-12 | Completed | ||
| Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19[NCT04944082] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Safety and Effectiveness Observational Study of Anti IL-6 Tocilizumab in Hospital Admitted Patients With Severe COVID-19 Pneumonia.[NCT04924829] | 300 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment[NCT04292730] | Phase 3 | 1,113 participants (Actual) | Interventional | 2020-03-15 | Completed | ||
| School Studies Within the EuCARE Horizon Europe Research Project (EUCARE-SCHOOLS Study)[NCT05396040] | 8,800 participants (Anticipated) | Interventional | 2022-05-10 | Recruiting | |||
| Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults[NCT04315948] | Phase 3 | 1,552 participants (Actual) | Interventional | 2020-03-22 | Completed | ||
| Acute Estradiol and Progesterone Therapy in Hospitalized Adults to Reduce Coronavirus Disease (COVID-19) Severity: A Randomized Control Trial[NCT04865029] | Phase 2 | 10 participants (Actual) | Interventional | 2021-07-22 | Terminated (stopped due to Lack of enrollment due to change of COVID 19 variant prevalence) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 16 |
| Placebo Control Group | 17 |
Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 6 |
| Placebo Control Group | 7 |
Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 11 |
| Placebo Control Group | 11 |
Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
The age of the patients (years) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Years (Mean) |
|---|---|
| Control Group | 66.23 |
| Study Group | 58.17 |
At the beginning of the study, the body temperatures (as degree celcius) of the patients were measured and the mean body temperature values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Degree celcius (Mean) |
|---|---|
| Control Group | 36.8 |
| Study Group | 36.9 |
At the beginning of the study, the heart rates (as per minute) of the patients were measured and the mean heart rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | beats per minute (Mean) |
|---|---|
| Control Group | 92 |
| Study Group | 88 |
The number of died patients were evaluated in study and control groups (NCT04646109)
Timeframe: Through study completion, an average of 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 9 |
| Study Group | 6 |
"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as clinical response: Extubation in mechanically ventilated patients, respiratory rate <26/min, SpO2 level in room air >90%, PaO2/FiO2 >300 in patients receiving oxygen, presence of at least two of the 2-point reduction criteria in Sequential Organ Failure Assessment (SOFA) score." (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 11 |
| Study Group | 14 |
"The presence of at least two of the following criteria in patients on the 10th day were accepted as clinical response: Respiration rate between 22-24/min, SpO2 level in room air >95%, absence of oxygen requirement, observation of radiological improvement in control lung tomography and no need for intensive care." (NCT04646109)
Timeframe: 10 days (5 days ivermectin therapy plus 5 days follow-up)
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 16 |
| Study Group | 22 |
At the end of the follow-up period (10th day), patients in the study and control group were investigated by PCR test for SARS-CoV-2 and the negative results were recorded as percentage for both groups. (NCT04646109)
Timeframe: At the end of 10th day
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 3 |
| Study Group | 14 |
At the beginning of the study, the respiratory rates (as per minute) of the patients were measured and the mean respiratory rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | breaths per minute (Mean) |
|---|---|
| Control Group | 24.7 |
| Study Group | 24 |
"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted." (NCT04646109)
Timeframe: From the 6th day of study to the 10th day of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 0 |
| Study Group | 0 |
Baseline SpO2 values of the patients were recorded in both groups. Then, their treatments were started and SpO2 values at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in SpO2 values on the 1st, 3rd and 5th days after the basal value calculated graphically, the change in the SpO2 value at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | percentage of peripheral capillary O2 (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 89.67 | 90.50 | 91.90 | 93.00 |
| Study Group | 89.93 | 92.85 | 93.07 | 93.52 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). SpO2 values at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in SpO2 values on the 6th, 8th and 10th days was calculated graphically, the change in the SpO2 value at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | percentage of peripheral capillary O2 (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 89.67 | 92.43 | 92.91 | 93.00 |
| Study Group | 89.93 | 94.54 | 94.24 | 95.35 |
Baseline serum D-dimer levels (mg/L) of the patients were recorded in both groups. Then, their treatments were started and serum D-dimer levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum D-dimer levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum D-dimer level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | mg/L (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 1.32 | 2.80 | 4.14 | 3.58 |
| Study Group | 1.25 | 1.40 | 3.24 | 5.85 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum D-dimer levels (mg/L) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in Serum D-dimer levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum D-dimer level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | mg/L (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 1.32 | 3.45 | 1.63 | 1.49 |
| Study Group | 1.25 | 1.37 | 0.89 | 0.71 |
Baseline serum ferritin levels (mg/dL) of the patients were recorded in both groups. Then, their treatments were started and serum ferritin levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum ferritin levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum ferritin level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 747.05 | 783.03 | 881.17 | 1028.24 |
| Study Group | 682.75 | 834.94 | 875.90 | 875.12 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum ferritin levels (mg/dL) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum ferritin levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum ferritin level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 747.05 | 1076.88 | 1097.57 | 1206.90 |
| Study Group | 682.75 | 628.45 | 433.48 | 494.71 |
Baseline Serum Lymphocyte counts (cell/mm^3) of the patients were recorded in both groups. Then, their treatments were started and Serum Lymphocyte counts at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in Serum Lymphocyte counts on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the Serum Lymphocyte count at the end of the 5th day (primary endpoint) with the baseline count was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | cell/mm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 1010 | 1034 | 977 | 968 |
| Study Group | 932 | 928 | 1021 | 1273 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum lymphocyte counts (cell/mm^3) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum lymphocyte counts on the 6th, 8th and 10th days was calculated graphically, the change in the serum lymphocyte count at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | cell/mm^3 (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 1010 | 916 | 1086 | 1256 |
| Study Group | 932 | 1403 | 1668 | 1698 |
Baseline PaO2/FiO2 ratios of the patients were recorded in both groups. Then, their treatments were started and PaO2/FiO2 ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PaO2/FiO2 ratios on the 1st, 3rd and 5th days after the basal ratio was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 197.44 | 181.83 | 174.77 | 180.13 |
| Study Group | 158.83 | 147.31 | 147.74 | 178.94 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PaO2/FiO2 ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PaO2/FiO2 ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 10th day (secondary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 197.44 | 204.28 | 211.75 | 220.78 |
| Study Group | 158.83 | 199.83 | 227.43 | 236.33 |
Baseline PNL/L ratio of the patients were recorded in both groups. Then, their treatments were started and PNL/L ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PNL/L ratios on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the PNL/L ratio at the end of the 5th day (primary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | TD1 | TD3 | TD5 | |
| Control Group | 7.48 | 7.74 | 9.26 | 9.88 |
| Study Group | 8.77 | 10.82 | 9.02 | 7.16 |
In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PNL/L ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PNL/L ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PNL/L ratio at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline | FD1 | FD3 | FD5 | |
| Control Group | 7.48 | 10.49 | 9.66 | 6.19 |
| Study Group | 8.77 | 6.90 | 5.81 | 7.34 |
The gender of patients (Male/female) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Male | Female | |
| Control Group | 19 | 11 |
| Study Group | 21 | 9 |
A blood sample was taken from the patients included in the study group, after taking or during the first dose of ivermectin. From the blood samples, haplotypes and mutations that cause the function losing were investigated by performing sequence analysis of multidrug resistance 1 (MDR1)/ABCB1 and CYP3A4 genes with Sanger method. In case of detection of mutation, the patient were excluded from the study and if observed, side effects of ivermectin were noted. (NCT04646109)
Timeframe: At the first day of ivermectin therapy (1st day)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Mutation positive | Mutation negative | |
| Control Group | 0 | 0 |
| Study Group | 6 | 30 |
"At the beginning of the study, the patients were asked whether there were any of the following accompanying diseases and the percentage of patients with accompanying disease in both groups were recorded:~Diabetes mellitus~Hypertension~Coronary artery disease~Cardiac failure~Chronic obstructive pulmonary disease~Malignancy~Immunodeficiency" (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Diabetes Mellitus | Hypertension | Coronary artery disease | Cardiac failure | Chronic obstructive pulmonary disease | Malignancy | Immunodeficiency | |
| Control Group | 10 | 12 | 8 | 1 | 3 | 1 | 1 |
| Study Group | 9 | 15 | 5 | 0 | 6 | 0 | 0 |
"At the beginning of the study, the patients were asked whether there were any of the following clinical symptoms and the percentage of patients with any of the clinical symptoms in both groups were recorded:~Fever~Cough~Sore throat~Dispnea~Headache~Weakness~Myalgia~Diarrhea~Nausea or vomiting" (NCT04646109)
Timeframe: At the first day of the study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fever | Cough | Sore throat | dyspnea | Headache | Weakness | Myalgia | Diarrhea | Nausea or vomiting | |
| Control Group | 13 | 14 | 1 | 19 | 2 | 11 | 7 | 0 | 0 |
| Study Group | 15 | 16 | 3 | 23 | 5 | 13 | 9 | 1 | 1 |
At the beginning of the study, the systolic and diastolic pressures (as mmHg) of the patients were measured and the mean systolic and diastolic pressure values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic pressure | Diastolic pressure | |
| Control Group | 124.61 | 73.43 |
| Study Group | 124.39 | 75.64 |
"Adverse effects of ivermectin and drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the study group and and the number of participants were noted.~Adverse effects of drugs other than ivermectin (Hydroxychloroquine, favipiravir, azithromycin) were evaluated in the patients in the control group and and the number of participants were noted." (NCT04646109)
Timeframe: At the first 5 days of study
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Nausea and vomiting | Increase in liver function tests | |
| Control Group | 2 | 1 |
| Study Group | 0 | 0 |
The mortality rate was determined as the proportion of participants who died by study Day 15. (NCT04280705)
Timeframe: Day 1 through Day 15
| Intervention | Proportion of participants (Number) |
|---|---|
| Placebo | 0.12 |
| Remdesivir | 0.07 |
The mortality rate was determined as the proportion of participants who died by study Day 29. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Proportion of participants (Number) |
|---|---|
| Placebo | 0.15 |
| Remdesivir | 0.11 |
Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 57 |
| Remdesivir | 51 |
An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 32 |
| Remdesivir | 24 |
New non-invasive ventilation or high-flow oxygen use was determined as the percentage of subject not on non-invasive ventilation or high-flow oxygen at baseline. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 24 |
| Remdesivir | 17 |
The percentage of participants requiring new oxygen use was determined as the percentage of participants not requiring oxygen at baseline (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 44 |
| Remdesivir | 36 |
The percentage of participants requiring new ventilator or ECMO use was determined as the percentage not on a ventilator or ECMO at baseline (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 23 |
| Remdesivir | 13 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Time to improvement by at least one category was determined for each participant (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 9 |
| Remdesivir | 7 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Time to improvement by at least two categories was determined for each participant (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 14 |
| Remdesivir | 11 |
The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. The time to discharge or a NEWS of less than or equal to 2 was determined for each participant. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 12 |
| Remdesivir | 8 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) |
|---|---|
| Placebo | 15 |
| Remdesivir | 10 |
Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | Units/Liter (U/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 14.3 | 23.1 | 24.2 | 27.7 | 28.1 | -3.9 |
| Remdesivir | 2.9 | 10.8 | 8.9 | 3.4 | 1.7 | -6.8 |
Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | Units/Liter (U/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 13.7 | 12.8 | 13.1 | 11.5 | 4.2 | -18.4 |
| Remdesivir | -2.0 | 6.0 | 1.1 | -0.3 | -2.3 | -14.0 |
Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.020 | 0.038 | 0.196 | 0.024 | 0.158 | 0.040 |
| Remdesivir | 0.005 | 0.005 | 0.005 | 0.028 | -0.058 | 0.029 |
Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | milligrams/deciliter (mg/dL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.037 | -0.695 | -0.882 | 1.173 | -1.239 | -1.863 |
| Remdesivir | 0.038 | 0.075 | 0.158 | 0.236 | 0.319 | 0.075 |
Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.634 | 0.666 | 0.596 | 0.093 | 1.992 | 0.241 |
| Remdesivir | 0.016 | -0.066 | -0.221 | -0.088 | -0.420 | 0.211 |
Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.2 | 6.3 | 2.2 | 1.0 | -2.8 | -13.5 |
| Remdesivir | -3.0 | 2.1 | 3.2 | -0.1 | -2.9 | -11.7 |
Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | grams/deciliter (g/dL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.52 | -0.83 | -1.22 | -1.66 | -1.51 | -1.02 |
| Remdesivir | -0.69 | -0.99 | -0.49 | -1.29 | -1.02 | -1.21 |
Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 5.883 | 4.064 | 8.006 | 0.393 | 14.793 | 0.668 |
| Remdesivir | -7.847 | -11.723 | -15.455 | -12.016 | -23.836 | 0.743 |
Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 2.448 | 1.498 | 2.324 | 0.383 | 6.475 | 0.125 |
| Remdesivir | -2.940 | -2.628 | -3.645 | -2.539 | -8.738 | 0.117 |
Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 9.429 | 4.177 | 17.916 | 3.010 | 36.024 | -1.269 |
| Remdesivir | -8.093 | -15.067 | -28.179 | -21.773 | -39.988 | -0.840 |
Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 39.3 | 76.5 | 111.8 | 109.3 | 96.5 | 32.7 |
| Remdesivir | 46.0 | 90.1 | 130.8 | 101.0 | 71.1 | 39.6 |
Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | -0.18 | -0.30 | 0.01 | 0.86 | 0.34 | -0.28 |
| Remdesivir | 0.44 | 1.15 | 1.43 | 1.88 | -0.03 | -0.63 |
Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 0.08 | 0.58 | 0.22 | 0.23 | 0.00 | -0.17 |
| Remdesivir | -0.04 | -0.03 | 0.01 | 0.07 | 0.09 | -0.12 |
Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15 and 29
| Intervention | 10^9 cells/liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 29 | |
| Placebo | 18.691 | 9.886 | 27.223 | 1.967 | 56.311 | -0.898 |
| Remdesivir | -18.970 | -28.209 | -45.997 | -34.702 | -70.884 | 0.251 |
The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. (NCT04280705)
Timeframe: Days 1, 3, 5, 8, 11, 15, 22, and 29
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 22 | Day 29 | |
| Placebo | 0.1 | 0.3 | -0.3 | -0.3 | -1.4 | -1.4 | -3.2 |
| Remdesivir | -0.3 | -0.4 | -0.5 | -0.5 | -1.7 | -1.7 | -3.3 |
Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputation for participants who died | Restricted to participants who did not die | |
| Placebo | 17 | 14 |
| Remdesivir | 12 | 10 |
Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 4 | 3 |
| Remdesivir | 3 | 3 |
"Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die~." (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 5.5 | 3 |
| Remdesivir | 4 | 3.5 |
Duration of new ventilator or ECMO use was measured in days among participants who were not on a ventilator or ECMO at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Including imputations for participants who died | Among participants who did not die | |
| Placebo | 23 | 16 |
| Remdesivir | 21.5 | 14 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement. (NCT04280705)
Timeframe: Day 1, 3, 5, 8, 11, 15, 22, and 29
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 8 | Day 11 | Day 15 | Day 22 | Day 29 | |
| Placebo | 0.2 | 0.1 | 0.0 | -0.1 | -1.4 | -1.9 | -2.3 |
| Remdesivir | 0.1 | 0.0 | -0.2 | -0.3 | -1.9 | -2.4 | -2.7 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 0 | 30 | 19 | 39 | 12 | 0 | 0 | 0 | 0 | 0 | 1 |
| Remdesivir | 0 | 24 | 18 | 43 | 14 | 0 | 0 | 0 | 1 | 0 | 1 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 11
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 8 | 28 | 7 | 13 | 6 | 2 | 0.4 | 0.2 | 0 | 33 | 2 |
| Remdesivir | 4 | 22 | 6 | 11 | 7 | 2 | 0.4 | 0 | 0 | 44 | 4 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 15
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 11 | 22 | 4 | 11 | 6 | 2 | 17 | 22 | 0 | 2 | 3 |
| Remdesivir | 6 | 15 | 4 | 10 | 7 | 3 | 19 | 29 | 0 | 2 | 5 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 22
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | Completed study without reporting score | |
| Placebo | 13 | 14 | 2 | 8 | 5 | 1 | 18 | 32 | 0 | 2 | 4 | 0 |
| Remdesivir | 9 | 9 | 2 | 5 | 6 | 1 | 19 | 39 | 0 | 3 | 6 | 0.2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 29
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | Completed study without reporting score | |
| Placebo | 15 | 9 | 2 | 4 | 3 | 1 | 19 | 36 | 0.2 | 3 | 5 | 3 |
| Remdesivir | 11 | 6 | 1 | 4 | 3 | 1 | 20 | 46 | 0 | 1 | 7 | 2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 3
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 1 | 36 | 17 | 32 | 12 | 0.4 | 0 | 0 | 0 | 0.2 | 1 |
| Remdesivir | 1 | 28 | 16 | 37 | 13 | 0.2 | 0 | 0.4 | 0 | 2 | 2 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 5
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 2 | 37 | 14 | 26 | 11 | 1 | 0 | 0.2 | 0 | 7 | 2 |
| Remdesivir | 2 | 28 | 12 | 28 | 15 | 1 | 0.2 | 0 | 0 | 12 | 3 |
The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 8
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Death at or before study Visit | Hospitalized, on invasive mech. vent. or ECMO | Hospitalized, on non-invasive vent./high flow O2 | Hospitalized, requiring supplemental oxygen | Hospitalized, not on O2, requiring ongoing care | Hospitalized, not requiring O2, no longer req care | Not hospitalized, limit on activities/req home O2 | Not hospitalized, no limitations on activities | No clinical status score reported - Hospitalized | No clinical status score reported - Discharged | No clinical status score reported - Discontinued | |
| Placebo | 7 | 33 | 9 | 15 | 10 | 1 | 0 | 0.2 | 0 | 22 | 2 |
| Remdesivir | 3 | 24 | 9 | 17 | 11 | 1 | 0.2 | 0 | 0.4 | 30 | 4 |
Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses. (NCT04280705)
Timeframe: Day 1 through Day 10
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Discontinued due to discharge | Discontinued due to death | Any infusions halted or slowed | Missed any maintenance dose | |
| Placebo | 30 | 4 | 2 | 21 |
| Remdesivir | 41 | 3 | 2 | 16 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Not Hispanic or Latino | Hispanic or Latino | |
| Placebo | 15.0 | 12.5 |
| Remdesivir | 10.0 | 10.0 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |||
|---|---|---|---|---|
| Asian | Black or African American | White | Other | |
| Placebo | 12.0 | 15.0 | 15.0 | 24.0 |
| Remdesivir | 11.0 | 10.0 | 9.0 | 9.0 |
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. (NCT04280705)
Timeframe: Day 1 through Day 29
| Intervention | Days (Median) | |
|---|---|---|
| Male | Female | |
| Placebo | 15.0 | 15.0 |
| Remdesivir | 9.0 | 10.0 |
Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study treatment start date and no later than 30 days after the permanent discontinuation of the study treatment and/or the AEs that led to premature discontinuation of study treatment. (NCT04292899)
Timeframe: First dose date up to last dose date (maximum: 10 days) plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Remdesivir (RDV) for 5 Days | 71.5 |
| Part A: Remdesivir for 10 Days | 75.1 |
"Clinical status was derived from death, hospital discharge, and the ordinal scale as follows: score of 1 was used for all days on or after the date of death; score of 7 was used for all days on or after discharged alive date; last assessment carried forward for any missing values.The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or ECMO; 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration); 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for the Remdesivir for 10 days group vs the Remdesivir for 5 days group." (NCT04292899)
Timeframe: Day 14
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Score: 1 | Score: 2 | Score: 3 | Score: 4 | Score: 5 | Score: 6 | Score: 7 | |
| Part A: Remdesivir (RDV) for 5 Days | 8.0 | 8.5 | 4.0 | 9.5 | 6.0 | 4.0 | 60.0 |
| Part A: Remdesivir for 10 Days | 10.7 | 16.8 | 5.1 | 7.6 | 6.1 | 1.5 | 52.3 |
TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent. (NCT04292730)
Timeframe: First dose date up to last dose date (maximum: 10 days) plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| Part A: Remdesivir for 5 Days | 51.3 |
| Part A: Remdesivir for 10 Days | 58.5 |
| Part A: SOC Therapy | 46.5 |
"Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of 1 was used for all days on or after the date of death; score of 7 was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group." (NCT04292730)
Timeframe: Day 11
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Score: 1 | Score: 2 | Score: 3 | Score: 4 | Score: 5 | Score: 6 | Score: 7 | |
| Part A: Remdesivir for 10 Days | 1.0 | 0.5 | 0.0 | 6.2 | 22.8 | 4.7 | 64.8 |
| Part A: Remdesivir for 5 Days | 0.0 | 0.0 | 2.6 | 3.7 | 19.9 | 3.7 | 70.2 |
| Part A: SOC Therapy | 2.0 | 2.0 | 3.5 | 5.5 | 23.0 | 4.0 | 60.0 |
Subjects will be followed daily for 7 days after initiation of treatment for adverse events. The investigators will review patients' medical records on day 14 and day 28. Then, the investigators will call patients on day 60. This will be done to determine the frequency and severity of adverse events in treatment arm vs. control arm. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | Participants (Number) |
|---|---|
| Estradiol and Progesterone Arm | 0 |
| Normal Saline and Folic Acid Arm | 0 |
The investigators will review patients' medical records on day 14 and day 28. Then, the investigators will call patients on day 60. This will be done to determine the efficiency of treatment on length of hospital stay. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | Days (Mean) |
|---|---|
| Estradiol and Progesterone Arm | 7.2 |
| Normal Saline and Folic Acid Arm | 10.2 |
The investigators will review patients' medical records on day 14 and day 28 and calculate number of deaths that occurred after admission. Then, the investigators will call patients on day 60. This will be done to determine the number of days death occurred after admission. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | Days (Number) |
|---|---|
| Normal Saline and Folic Acid Arm | 19 |
"The proportion will be calculated based on WHO ordinal scale for clinical improvement. The scale is from 0 to 8, with a higher score indicating worse clinical status.~Uninfected: No clinical or virological evidence of infection 0~Ambulatory: No limitation of activities 1 Limitation of activities 2~Hospitalized Mild Disease Hospitalized, no oxygen therapy 3 Oxygen by mask or nasal prongs 4~Hospitalized Severe Disease Non-invasive ventilation or high flow oxygen 5 Intubation and mechanical ventilation 6 Ventilation + additional organ support - 7 pressors, Renal Replacement Therapy (RRT), Extracorporeal Membrane Oxygenation (ECMO)~Dead Death 8" (NCT04865029)
Timeframe: At discharge, measured up to Day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| Estradiol and Progesterone Arm | 5 |
| Normal Saline and Folic Acid Arm | 4 |
The investigators will review patients' medical records on day 14 and day 28. Then, the investigators will call patients on day 60. This will be done to determine the number of patients requiring invasive mechanical ventilation (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | Participants (Number) |
|---|---|
| Estradiol and Progesterone Arm | 0 |
| Normal Saline and Folic Acid Arm | 1 |
Subjects will be followed daily for 7 days after initiation of treatment for serious adverse events. The investigators will review patients' medical records on day 14 and day 28. Then, the investigators will call patients on day 60. This will be done to determine the frequency of serious adverse events in treatment arm vs. control arm. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | Participants (Number) |
|---|---|
| Estradiol and Progesterone Arm | 0 |
| Normal Saline and Folic Acid Arm | 1 |
The investigators will review patients' medical records on day 14 and day 28 and determine the cause of death. Then, the investigators will call patients on day 60. This will be done to determine the cause of death. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | participants (Number) | |
|---|---|---|
| Death from COVID-19 | Death from bacteremia | |
| Estradiol and Progesterone Arm | 0 | 0 |
| Normal Saline and Folic Acid Arm | 0 | 1 |
The investigators will review patients' medical records on day 14 and day 28. Then, the investigators will call patients on day 60. This will be done to determine the readmission rates. (NCT04865029)
Timeframe: Baseline to day 60
| Intervention | participants (Number) | |
|---|---|---|
| COVID related readmission number | Non-COVID related readmission number | |
| Estradiol and Progesterone Arm | 0 | 0 |
| Normal Saline and Folic Acid Arm | 0 | 1 |
85 reviews available for alanine and Pneumonia, Viral
| Article | Year |
|---|---|
Understanding of COVID-19 based on current evidence.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Animals; Antiviral Agents; Betacoronaviru | 2020 |
Understanding of COVID-19 based on current evidence.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Animals; Antiviral Agents; Betacoronaviru | 2020 |
Understanding of COVID-19 based on current evidence.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Animals; Antiviral Agents; Betacoronaviru | 2020 |
Understanding of COVID-19 based on current evidence.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Animals; Antiviral Agents; Betacoronaviru | 2020 |
Clinical trial analysis of 2019-nCoV therapy registered in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cli | 2020 |
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus | 2020 |
[Pharmacotherapeutics for the new coronavirus pneumonia].
Topics: Adenosine; Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antiviral Agents; China; Coronav | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Alanine; Asymptomatic Infections; Betacoronavirus; | 2020 |
[Remdesivir, the antiviral hope against SARS-CoV-2].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Potential therapeutic agents against COVID-19: What we know so far.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; | 2020 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi | 2020 |
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronaviru | 2020 |
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir | 2020 |
Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; China; Communicable Disease Con | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavir | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; | 2020 |
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting En | 2020 |
[Remdesivir for patients with severe COVID-19].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; Humans; Pandem | 2020 |
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin-Converting Enzyme Inh | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betac | 2020 |
Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Bone Marrow Transplantation; Clinical Laboratory | 2020 |
Medical treatment options for COVID-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Human | 2020 |
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En | 2020 |
Rapid review for the anti-coronavirus effect of remdesivir.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Top | 2020 |
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Coronav | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir | 2020 |
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Cardiovascul | 2020 |
Just the facts: What drugs are safe and effective for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; A | 2020 |
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Educational case series of electrocardiographs during the COVID-19 pandemic and the implications for therapy.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronav | 2020 |
A current review of COVID-19 for the cardiovascular specialist.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Biomarkers; Card | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; | 2020 |
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Topics: Acetylcysteine; Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Anti-Inflammatory Agents; | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Beta | 2020 |
Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Alanine; Antiviral Agents; Cause of Death; Comorbidity | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Cor | 2020 |
Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
[COVID-19 trials: surfing between expectations and illusions, looking forward to evidence].
Topics: Adenosine Monophosphate; Alanine; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroqui | 2020 |
Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2020 |
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coron | 2020 |
Emerging pharmacotherapy for COVID-19.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coron | 2020 |
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mono | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infe | 2020 |
Current pharmacological treatments for SARS-COV-2: A narrative review.
Topics: Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Antiviral Agents; Betacoronavirus; Clinica | 2020 |
Clinical management of COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Airway Management; Alanine; Antibodies, Monoclonal | 2020 |
Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Topics: Adenosine Monophosphate; Age Factors; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; As | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavir | 2020 |
Is hydroxychloroquine beneficial for COVID-19 patients?
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chlor | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized | 2020 |
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimala | 2020 |
Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.
Topics: Adenosine Monophosphate; Alanine; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; A | 2020 |
Use of remdesivir for patients with Covid-19: a review article.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; | 2020 |
Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Antiviral Agents; Betacoronavirus; Cl | 2020 |
COVID-19 and liver disease: An update.
Topics: Adenosine Monophosphate; Age Factors; Alanine; Antiviral Agents; Betacoronavirus; Bile Ducts; Chemic | 2020 |
Drug treatments for covid-19: living systematic review and network meta-analysis
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Centers for Disease Control and | 2020 |
Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Asymptomatic Diseases; Betacoronavirus; Biomarke | 2020 |
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Coronavirus I | 2020 |
A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Clinical Trials as Topic; Coronavirus I | 2020 |
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; Betacoronavirus; Coronavirus In | 2020 |
Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2.
Topics: Adenosine Monophosphate; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; | 2020 |
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavir | 2020 |
Remdesivir: First Approval.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
A contemporary look at COVID-19 medications: available and potentially effective drugs.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacor | 2020 |
Advances in SARS-CoV-2: a systematic review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicista | 2020 |
Remdesivir-COVID-19: drug interactions in dentistry.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Systemic Medications of Dermatological Importance in COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Biological Products; Coronavirus Infections; COV | 2020 |
Remdesivir against COVID-19 and Other Viral Diseases.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Compa | 2020 |
Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal; Antibodie | 2020 |
Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.
Topics: Adenosine Monophosphate; Aged, 80 and over; Alanine; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pneumoni | 2021 |
8 trials available for alanine and Pneumonia, Viral
| Article | Year |
|---|---|
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; Comp | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; China; Coronavirus Infect | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Remdesivir for the Treatment of Covid-19 - Final Report.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; China; Clinical Trials, Phase I | 2020 |
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infect | 2020 |
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Alanine; Antiviral Agents; Area Under C | 2020 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Alanine; Antiviral Agents; Betacoronavir | 2020 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Alanine; Antiviral Agents; Betacoronavir | 2020 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Alanine; Antiviral Agents; Betacoronavir | 2020 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Alanine; Antiviral Agents; Betacoronavir | 2020 |
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
158 other studies available for alanine and Pneumonia, Viral
| Article | Year |
|---|---|
SARS-CoV-2 Infection in an Adolescent With X-linked Agammaglobulinemia.
Topics: Adenosine Monophosphate; Adolescent; Agammaglobulinemia; Alanine; Antibodies, Viral; Antiviral Agent | 2021 |
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2022 |
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2022 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antimalarials; Antiviral Agents; Betacoronavirus; Biologi | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
More than 80 clinical trials launch to test coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Cli | 2020 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoron | 2020 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoron | 2020 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoron | 2020 |
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoron | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Breastfeeding and Respiratory Antivirals: Coronavirus and Influenza.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Breast Feeding; Coronavirus Inf | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Top | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical S | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; | 2020 |
Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Topics: Adenosine Monophosphate; Alanine; Analgesia; Antiviral Agents; Betacoronavirus; China; Compassionate | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquin | 2020 |
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus; Coronavi | 2020 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronaviru | 2020 |
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibiotic Prophylaxis; Antiviral Agents; Betacoronavirus | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Alanine; Antiv | 2020 |
Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.
Topics: Adenosine Monophosphate; Adult; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavir | 2020 |
Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coron | 2020 |
Early impact of COVID-19 on transplant center practices and policies in the United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Clinical Labor | 2020 |
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; Betacoronavirus; Catalytic Doma | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infe | 2020 |
COVID-2019: update on epidemiology, disease spread and management.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Basic Reproduct | 2020 |
The race against COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Viral; Antiviral Agents; Betacoronavirus; Clinical Lab | 2020 |
COVID-19 in a high-risk dual heart and kidney transplant recipient.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Cardiomyopathy, Dilated; Coronavirus Infec | 2020 |
Remdesivir in covid-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Compassionate Use Trials; Coronavirus Infections; | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiote | 2020 |
Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Aquatic Organisms; Biological Products; Chloroqu | 2020 |
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; | 2020 |
Chloroquine hype is derailing the search for coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
The clinical manifestations and management of COVID-19-related liver injury.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Coronavirus; Coronavirus Infections; | 2020 |
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavir | 2020 |
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Alanine; Betacoronavirus; Chromatography, High Pres | 2020 |
The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Topics: ADAM17 Protein; Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; | 2020 |
Audio Interview: Studying Potential Covid-19 Therapies.
Topics: Adenosine Monophosphate; Alanine; Anti-Infective Agents; Azithromycin; Betacoronavirus; Controlled C | 2020 |
When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Biomedical Res | 2020 |
Novel coronavirus 2019 (COVID-19): A case report and review of treatments.
Topics: Adenosine Monophosphate; Aged; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical L | 2020 |
[Chloroquine as a possible treatment for COVID-19].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infect | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; | 2020 |
In Vitro Data of Current Therapies for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID | 2020 |
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Antic | 2020 |
Coronavirus drugs trials must get bigger and more collaborative.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Compassionate Use Trials; Coronavirus; Coronaviru | 2020 |
Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020.
Topics: Adenosine Monophosphate; Aged; Aged, 80 and over; Alanine; Asthma; Azithromycin; Betacoronavirus; Ca | 2020 |
Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antiviral Agents; Asthma; Betacoronavirus; Blood Urea | 2020 |
Dozens of coronavirus drugs are in development - what happens next?
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Coronavirus I | 2020 |
Compassionate Use of Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Compassionate Use of Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Compassionate Use of Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Compassionate Use of Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Compassionate Use of Remdesivir in Covid-19. Reply.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Compassionate Use Trials; Coron | 2020 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Protect Pregnant and Lactating Women with COVID-19 Through Research, Not from Research.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Breast Feeding; Coronavirus Inf | 2020 |
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision- | 2020 |
Remdesivir for COVID-19: challenges of underpowered studies.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Does lopinavir really inhibit SARS-CoV-2?
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronaviru | 2020 |
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Topics: Adenosine Monophosphate; Administration, Inhalation; Administration, Intravenous; Alanine; Animals; | 2020 |
Remdesivir - An Important First Step.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Audio Interview: New Data on Remdesivir in Covid-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Interactio | 2020 |
An update on novel COVID-19 pandemic: a battle between humans and virus.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adolescent; Adult; Alanine; Antiviral Agents; Child; Child, Preschool; Coro | 2020 |
Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
[Remdesivir til behandling af COVID-19-pneumoni].
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemi | 2020 |
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Betacoronavirus; Bronchoalveolar Lavage Fluid; Coronaviru | 2020 |
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; | 2020 |
Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Blood Cell Count; California; C | 2020 |
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
Uncertainty about the Efficacy of Remdesivir on COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Coronavirus breakthrough: dexamethasone is first drug shown to save lives.
Topics: Adenosine Monophosphate; Alanine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critica | 2020 |
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infec | 2020 |
[Remdesivir for patients with COVID-19].
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chromatography, Liqu | 2020 |
A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Missed Opportunities on Emergency Remdesivir Use.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Clinical Trials, Phase III as T | 2020 |
Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Optimizing Medication Management During the COVID-19 Pandemic: It Takes a Village.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy; H | 2020 |
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; C | 2020 |
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; C | 2020 |
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; C | 2020 |
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; C | 2020 |
Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biological Products; Catalytic | 2020 |
Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Adult; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betaco | 2020 |
Case report study of the first five COVID-19 patients treated with remdesivir in France.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Antiviral Agents; Betacoronavirus; | 2020 |
Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Ampicillin; Angioedema; Betacoronavirus; Coronavirus Infect | 2020 |
Remdesivir for the Treatment of Covid-19 - Preliminary Report.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Remdesivir for the Treatment of Covid-19 - Preliminary Report.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Remdesivir for the Treatment of Covid-19 - Preliminary Report.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Remdesivir for the Treatment of Covid-19 - Preliminary Report.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Child, Preschool; Coronavirus Infections; COVID-1 | 2020 |
COVID-19 Therapeutics: Making Sense of It All.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Berberine; Betacoronavirus; Chlorocebus | 2020 |
Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
Topics: Adenosine Monophosphate; Adolescent; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus | 2020 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Betacoronavirus; Clinical Decision-Making; Coro | 2020 |
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Topics: Adenosine Monophosphate; Alanine; Alveolar Epithelial Cells; Antiviral Agents; Betacoronavirus; Cell | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Bin | 2020 |
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver | 2020 |
Liver injury in remdesivir-treated COVID-19 patients.
Topics: Adenosine Monophosphate; Administration, Intravenous; Adult; Aged; Alanine; Antiviral Agents; Betaco | 2020 |
[COVID-19: a cardiological point-of-view].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Arteritis; Betacoronavirus; Cardiovascular Disea | 2020 |
Remdesivir for severe covid-19: a clinical practice guideline.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Communicating Science in the Time of a Pandemic.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Communication; Coronavirus Infe | 2020 |
Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice.
Topics: Adaptation, Physiological; Adenosine Monophosphate; Administration, Intranasal; Alanine; Animals; Be | 2020 |
BET 1: The role of remdesivir in COVID-19 infection.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic | 2020 |
Treatments for COVID-19: where are we now?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Were it business opportunities or hidden risks: Observations on clinical trials and marketing authorizations of Gilead Science's remdesivir in China.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; China; Clinical Trials as Topic; Coronavirus Inf | 2020 |
Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; Female; | 2020 |
Experts Discuss COVID-19-Remdesivir, Vaccines, and More.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Contact Tracing; Coronavirus In | 2020 |
Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach.
Topics: Adenosine Monophosphate; Alanine; Algorithms; Antiviral Agents; Betacoronavirus; Cohort Studies; Com | 2020 |
A Chemoenzymatic Synthesis of the (
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Caulobacteraceae; Coronavirus I | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Bilateral posterior cerebral artery territory infarction in a SARS-Cov-2 infected patient: discussion about an unusual case.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Efficacy of Remdesivir in COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; C | 2020 |
Allocating Remdesivir Under Scarcity: Social Justice or More Systemic Racism.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Antiviral treatment for COVID-19: the evidence supporting remdesivir.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Antiviral Agents; Betacoronavirus; Co | 2020 |
Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; China; Clinical Trials Data Mon | 2020 |
Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Antiviral Agents; beta-Cyclodextrins; Betacoronavirus; | 2020 |
It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.
Topics: Adenosine Monophosphate; Alanine; Antitubercular Agents; Antiviral Agents; Betacoronavirus; Coinfect | 2020 |
Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Remdesivir and COVID-19: What are the implications for Africa?
Topics: Adenosine Monophosphate; Africa; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections | 2020 |
Remdesivir, a remedy or a ripple in severe COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Kidney Transplantation and COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavir | 2020 |
COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Neutralizing; Antiviral Agents; Coronavirus Infections | 2020 |
COVID-19: Rescue by transcriptional inhibition.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Pulmonary administration of remdesivir in the treatment of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibo | 2020 |
Compassionate Drug Use - Time Arising for a New Law in Bulgaria in the Era of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bulgaria; Compassionate Use Tri | 2020 |
Remdesivir and COVID-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Remdesivir and COVID-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Remdesivir and COVID-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Remdesivir and COVID-19 - Authors' reply.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Coronav | 2020 |
Audio Interview: Covid-19 and the President.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Coronav | 2020 |
Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agent | 2020 |
Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.
Topics: Adenosine Monophosphate; Alanine; Amidines; Antiviral Agents; Chemistry Techniques, Synthetic; Coron | 2020 |
Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug | 2021 |
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections; | 2020 |
Why do COVID death rates seem to be falling?
Topics: Adenosine Monophosphate; Age Distribution; Age Factors; Aged; Aged, 80 and over; Alanine; Antibodies | 2020 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; | 2020 |
Audio Interview: What the U.S. Response to Covid-19 Looks Like Today.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal; Antiviral Agents; Asymptomatic Diseases; B | 2020 |
[Nursing Experience Caring for a COVID-19 Patient With Hearing Loss].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Communication; Coronavirus Infections; COVID-19; | 2020 |
Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antiviral Agents; COVID-19; COVID-19 Serotherapy; Fema | 2021 |
Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Topics: Adenosine Monophosphate; Airway Management; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treat | 2021 |
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pneumonia, Vira | 2021 |
A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Dexamethasone; Dr | 2021 |
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Topics: Adenosine Monophosphate; Alanine; B-Lymphocytes; Combined Modality Therapy; COVID-19; COVID-19 Drug | 2021 |